Diketone compound as well as preparation method and application thereof

By designing and preparing diketone compounds with general formula A structure, the problem of insufficient activity of existing targeted eEF2K compounds is solved, and the efficient binding of eEF2K and significant inhibition of anti-malignant tumor cells is achieved, with good safety and application value.

CN118994100AActive Publication Date: 2024-11-22SUZHOU UNIV +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202410634069.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2024-05-21
Publication Date
2024-11-22
Estimated Expiration
2044-05-21

AI Technical Summary

Technical Problem

Existing small-molecule compounds targeting eEF2K have weak cellular inhibitory activity or low degradation rates, making it difficult to effectively inhibit the growth of malignant tumor cells.

Method used

A diketone compound has been designed with the structure of general formula A, which is prepared by diazotization coupling reaction, ring-closing reaction, substitution reaction and acid chloride reaction under acidic and alkaline conditions, and has strong eEF2K binding ability and Anti-malignant tumor cell activity.

Benefits of technology

It has achieved efficient binding and inhibition of eEF2K, significantly improved the inhibitory activity of malignant tumor cells, and at the same time it has low toxicity to normal cytotoxicity and good safety, and has important application value for anti-tumor drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994100A_ABST
    Figure CN118994100A_ABST
Patent Text Reader

Abstract

The invention relates to a diketone compound as well as a preparation method and application thereof. The structural formula of the diketone compound disclosed by the invention is as shown in a formula A: # imgabs0 #; wherein # imgabs 1 # and # imgabs 2 # are independently selected from a substituted or unsubstituted aryl group or heteroaryl group; x is carbonyl or alkyl; y is substituted or unsubstituted alkyl; z is N or CH; r1 and R2 are independently selected from hydrogen or other groups and cannot be hydrogen at the same time, or R1 and R2 form substituted or unsubstituted heterocyclic groups together with nitrogen atoms to which R1 and R2 are connected; r1 and R2 can be the same or different. The invention designs and synthesizes a compound with a structure of a general formula A, and finds that the compound shows relatively strong binding capacity and in-vitro cell inhibition activity on eEF2K, and has good selectivity. The invention reveals and clarifies the relationship between the structure and activity of the compounds more deeply and comprehensively in a larger range, and has more important application value. The compound provided by the invention can be used for treating malignant tumors when acting on eEF2K.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of pharmaceutical chemistry, and in particular to a diketone compound or an isomer thereof, a preparation method thereof and use thereof in preparing a drug for preventing and / or treating malignant tumors associated with eEF2K. Background Art

[0003] Currently, commonly used anti-tumor drugs include biological alkylating compounds, antimetabolites, antibiotics, natural products and their derivatives, and protein tyrosine kinase inhibitors. However, these anti-malignant tumor drugs have many disadvantages, such as: biological alkylating compounds will inhibit other rapidly proliferating cells when inhibiting tumor cells, and this type of compound is also very easy to develop drug resistance; antimetabolites have a narrow anti-tumor spectrum; antibiotic compounds have high bone marrow suppression toxicity; the source of natural products is limited, and total synthesis is difficult. Therefore, it is urgent to develop anti-tumor drugs with low toxicity, high activity, and simple sources.

[0004] Eukaryotic elongation factor 2 kinase (eEF2K), as a member of the α-kinase family of atypical kinases, is a calcium / calmodulin-dependent kinase with unique structure and function. It participates in the calmodulin-mediated signaling pathway in the human body, catalyzing the phosphorylation of the Thr56 site of eukaryotic elongation factor-2 (eEF2) and causing its inactivation, thereby inhibiting the protein peptide chain elongation process of mRNA translation.

[0005] eEF2K is highly expressed in a variety of malignant tumor cells, such as lung cancer, colon cancer, breast cancer and esophageal cancer. When normal tissues encounter nutrient deficiency, mTORC and Erk are inhibited, and the AMP / ATP ratio increases, thereby activating eEF2K to phosphorylate eEF2 and inhibit protein synthesis, promote cell autophagy, reduce the tumor cells' need for peripheral environmental nutrition, and ultimately increase the survival rate of tumor cells; conversely, when eEF2K is inhibited, the growth of tumor cells will be inhibited ( Lung Cancer ,2018, 124, 31–39; Oncotarget, 2017 , 8, 11641-11658; Radiother Oncol. 2017, 124,439–447; Apoptosis . 2014, 19, 241–258; Cell , 2013, 153, 1064–1079). In summary, eEF2K is a very promising target for the treatment of malignant tumors, and small molecule compounds targeting eEF2K protein are expected to alleviate or treat malignant tumors.

[0006] A variety of small molecule compounds targeting eEF2K have been discovered, including inhibitors and protein degradation targeting complexes (PROTACs) (Int. J. Mol. Sci. 2021, 22, 2408), such as the selective eEF2K inhibitor A-484954 developed by Abbott, which inhibits eEF2K by competing for ATP binding to eEF2K (IC 50 = 0.28 μM), but the cell activity was weak (IC 50 > 20 μM) J. Biol. Chem. 2011, 286, 43951–44398; Bioorg. Med. Chem. 2014, 22, 4910–4916). In addition, PROTAC derivatives of A-484954 were found, and their maximum degradation rate (Dr) of eEF2K was only 56.7%. Therefore, these compounds are currently only used as pharmacological tools. Summary of the invention

[0007] To this end, the technical problem to be solved by the present invention is to overcome the shortcomings of the existing small molecule compounds targeting eEF2K in the prior art, such as weak cell inhibitory activity or low degradation rate. In order to solve the above technical problems, the present invention provides a diketone compound and its anti-malignant tumor application related to eEF2K.

[0008] The first object of the present invention is to provide a diketone compound, the structural formula of which is shown in Formula A: ; in, , Independently selected from substituted or unsubstituted aryl or heteroaryl; X is a carbonyl or alkyl, Y is a substituted or unsubstituted alkyl, and Z is N or CH; preferably, X is a carbonyl C=O, or an alkyl with a chain length of C1-C3, and Y is a substituted or unsubstituted C1-C3 alkyl; R 1 and R 2 R is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclic, ester, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, both of which cannot be hydrogen at the same time; or 1 and R 2 Together with the nitrogen atom to which they are attached, they form a substituted or unsubstituted heterocyclic group; R 1 and R 2 Can be the same or different; Furthermore, in the substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkynyl, the number of carbon atoms of the alkyl, alkenyl, and alkynyl is 1 to 10; in the substituted or unsubstituted heterocyclic group, the heterocyclic ring is a 3-8-membered monocyclic ring or a 6-20-membered polycyclic ring; in the substituted alkyl, substituted heterocyclic group, substituted alkenyl, substituted alkynyl, and substituted aryl, the substituents are independently selected from one or more of halogen, alkyl, alkoxy, haloalkyl, silane, aralkyl, heteroaryl, hydroxyl, hydroxyalkoxy, hydroxyalkyl, alkoxyalkoxy, alkoxyalkyl, aminealkyl, aminealkoxy, amino, alkylamino, hydroxyalkylamino, aminealkylamino, alkoxyacyl, alkoxycarbonylamino, cyano, acyloxy, acyl, sulfonyl, carbamoyl, sulfonylamino, nitro, urea, and thiourea.

[0009] In one embodiment of the present invention, the R 1 and R 2 By several R 3 replaced; said R 3 One or more selected from halogen, C1-C6 alkyl, haloalkyl, silane, aralkyl, heteroaryl, alkoxy, hydroxy, hydroxyalkoxy, hydroxyalkyl, alkoxyalkoxy, alkoxyalkyl, aminealkyl, aminealkoxy, amino, alkylamino, hydroxyalkylamino, aminealkylamino, alkoxyacyl, alkoxycarbonylamino, cyano, acyloxy, acyl, sulfonyl, sulfonylamino, urea, thiourea, nitro, carbamoyl. The number of them can be 1-3, and can be specifically 1, 2, or 3. R 1 and R 2 By several R 3 The substituted 1 and R 2 The heterocyclic group formed together with the nitrogen atom to which they are attached is composed of several R 3 Replace, or R 1 and R 2 Independently by several R 3 replace.

[0010] Furthermore, R 1 and R 2 are the same or different and are independently selected from hydrogen, C1-C10 alkyl, substituted or unsubstituted aryl, which may be optionally replaced by 1-3 identical or different R 3 Replace, but R 1 and R 2 Cannot be hydrogen at the same time; or R 1 and R 2 Together with the nitrogen atom to which they are connected, they form a substituted or unsubstituted 3-10 membered heterocyclic group, including a monocyclic, bicyclic or tricyclic ring, which may be a bridged ring or a spirocyclic ring, which may optionally include 0, 1 or 2 carbon-carbon double bonds, and further a 5-7 membered heterocyclic group, preferably a 6 membered heterocyclic group. The structural formula (A') is shown below, and the dotted line in the molecular formula represents R 1and R 2 Can be looped:

[0011] R 3 is halogen, C1-C6 alkyl, haloalkyl, silyl, aralkyl, heteroaryl, alkoxy, hydroxy, hydroxyalkoxy, hydroxyalkyl, alkoxyalkoxy, alkoxyalkyl, aminealkyl, aminealkoxy, amino, alkylamino, hydroxyalkylamino, aminealkylamino, alkoxyacyl, alkoxycarbonylamino, cyano, carboxyl, acyloxy, acyl, sulfonyl, sulfonylamino, urea, nitro, thiourea and carbamoyl; further, R 3 is halogen, C1-C6 alkyl, cyano, acyloxy, acyl, sulfonyl and carbamoyl; further, R 3 is fluorine, acyloxy, or carbamate. 1 and R 2 In addition to the nitrogen atom to which it is attached, the heterocyclic group optionally includes 0, 1 or 2 carbon-carbon double bonds, the heterocyclic group and the heteroaryl group.

[0012] In the present invention, alkyl refers to branched alkyl, straight chain alkyl, cycloalkyl, halogenated alkyl, nitrogen-containing alkyl, aralkyl, etc.; aryl refers to substituted or unsubstituted aryl or heteroaryl.

[0013] Furthermore, the alkyl group may be a branched alkyl group, a straight alkyl group or a cycloalkyl group of C3, C4, C5, C6, C7, C8, C9 or C10. The alkyl group in the C3-C10 nitrogen-containing alkyl group may be C3, C4, C5, C6, C7, C8, C9 or C10, and may optionally contain 0 to 4 heteroatoms selected from N and O (preferably 1 to 4), including piperidine ring, piperazine ring, homopiperazine ring, morpholine ring, etc. The aralkyl group may be a phenyl ring, a naphthalene ring, a biphenyl ring, or a nitrogen-containing heterocyclic ring such as a pyridine ring.

[0014] Furthermore, the C1-C6 alkyl group may be an alkyl group of C1, C2, C3, C4, C5, or C6.

[0015] Furthermore, the C1-C10 alkyl group may be a cycloalkyl group, a chain alkyl group, a halogenated alkyl group, a nitrogen-containing alkyl group or an aryl alkyl group of C1, C2, C3, C4, C5, C6, C7, C8, C9, or C10; the C1-C6 alkyl group may be a cycloalkyl group or a chain alkyl group of C1, C2, C3, C4, C5, or C6; the C1-C3 alkyl group may be a cycloalkyl group or a chain alkyl group of C1, C2, or C3.

[0016] In one embodiment of the present invention, the substituted or unsubstituted aryl or heteroaryl is a substituted or unsubstituted benzene ring, a naphthalene ring, a biphenyl ring, or an aromatic heterocyclic ring composed of one or more N, O, and S, wherein N, O, and S may exist alone, simultaneously, or in pairs. Specifically, the substituted or unsubstituted heteroaryl is selected from a substituted or unsubstituted pyrrole ring, a pyrazole ring, a furan ring, a thiophene ring, a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, an imidazole ring, a pyridine ring, ring, pyrazine ring, pyrimidine ring, pyridazine ring, triazole, naphthalene ring, benzoaromatic heterocycle (not limited to quinoline ring, isoquinoline ring, indole ring, quinazoline, benzofuran ring, benzothiophene ring, benzothiazole ring, benzoxazole ring, benzisoxazole ring, benzothiazole ring, indazole ring, benzimidazole ring, benzotriazole ring), benzocycloalkanes (not limited to indoline ring, isoindoline ring, tetrahydroisoquinoline ring, tetrahydroquinoline ring, benzazepine, benzoxazepine, benzoxazepine), etc. The substituents in the substituted or unsubstituted aryl or heteroaryl are selected from one or more of hydrogen, alkyl, haloalkyl, silyl, aralkyl, heteroaryl, alkoxy, haloalkoxy, hydroxyl, hydroxyalkoxy, hydroxyalkyl, alkoxyalkoxy, alkoxyalkyl, aminealkoxy, amino, aminealkyl, alkylamino, hydroxyalkylamino, aminealkylamino, halogen, cyano, acyloxy, carbamoyl, sulfonylamino, urea, thiourea, nitro, acyl and sulfonyl.

[0017] In one embodiment of the present invention, The substituted or unsubstituted aryl or heteroaryl group is selected from a substituted or unsubstituted benzene ring, a naphthalene ring, a quinoline ring, an isoquinoline ring, an indole ring, a quinazoline, an indoline ring, an isoindoline ring, a tetrahydroisoquinoline ring, a tetrahydroquinoline ring, a benzazepine, a benzoxazepine, and a benzoxazepine; further preferably 3,4-dimethylphenyl, 5,6,7,8-tetrahydronaphthalene-2-amine, 2,3-dihydro-1H-indene-5-amine, tetrahydroisoquinolyl, and tetrahydroquinolyl. Selected from substituted or unsubstituted aryl or heteroaryl, selected from substituted or unsubstituted phenyl, naphthalene ring, biphenyl ring, pyridine ring, triazole, the substituent group used is selected from one or more of halogen, alkyl, alkoxy, nitro, amino, hydroxyalkoxy, alkoxyalkoxy, acyloxy, acyl and sulfonyl. Preferred are phenyl, 3-fluorophenyl, 2-fluorophenyl, 2-methylphenyl, 3-methylphenyl, 3-chlorophenyl, 2-chlorophenyl, 3-methoxyphenyl, 2-methoxyphenyl, 3-trifluoromethylphenyl, 2-trifluoromethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, 3-nitrophenyl, 2-nitrophenyl, 3-hydroxyphenyl, 2-hydroxyphenyl, 3-aminophenyl, 2-aminophenyl, hydroxyethoxyphenyl, methoxyethoxyphenyl, pyridyl and triazolyl.

[0018] Preferably, the diketone compound is the following compound (the compound prepared in the embodiment of the present invention): ; ; ; ;

[0019] The second object of the present invention is to provide a method for preparing the diketone compound, comprising the following preparation method: Method 1: (1) subjecting the compound represented by formula A1 to a compound represented by formula A2 through a diazotization coupling reaction to obtain a compound represented by formula A3; (2) The compound represented by formula A3 is subjected to ring closure under acidic conditions to obtain the compound represented by formula A4, and the compound represented by formula A4 undergoes substitution reaction with a halogenated hydrocarbon under alkaline conditions to obtain the compound represented by formula A5; (3) The cyano group of the compound represented by formula A5 is hydrolyzed under acidic conditions to obtain a compound represented by formula A6 containing a carboxylic acid; (4) The compound represented by formula A6 is prepared into an acyl chloride compound represented by formula A7, and reacted with an amine compound to obtain a compound represented by formula A, i.e., the diketone compound; Or method 2: (1) reacting the compound represented by formula B1 with the compound represented by formula B2 to obtain the compound represented by formula B3; (2) the compound represented by formula B3 reacts under alkaline conditions to obtain the compound represented by formula B4, and the compound represented by formula B4 reacts to obtain the compound represented by formula B5; (3) the compound represented by formula B5 is reacted to obtain the compound represented by formula B6 containing carboxylic acid; or the compound represented by formula B5 is reacted with an amine compound to obtain the diketone compound; (4) The compound represented by formula B6 reacts with an amine compound to prepare the diketone compound; Or method three: (1) reacting the cyano group of the compound represented by formula A5 to obtain the compound represented by formula C2 containing an amine group; (2) preparing the diketone compound from the compound represented by formula C2; The structural formula of the above compound is as follows: ;

[0020] The structural formula of the amine compound is shown below: The structural formula of halogenated hydrocarbons is shown below:

[0021] In the above structural formula, the selection of substituents is consistent with the above.

[0022] In the above technical scheme, in method 1, the molar ratio of the compound represented by formula A1 to the compound represented by formula A2 is 1:1-1:2, the acidic condition is a pH value of 1-4; the alkaline condition is a pH value of 8-10, and the compound represented by formula A6 is subjected to an acyl chlorination reaction under the action of a catalyst to prepare an acyl chloride compound represented by formula A7; In method 2, the reaction of the compound represented by formula B1 and the compound represented by formula B2 is carried out under a copper salt catalyst and a base catalyst, the compound represented by formula B3 is reacted under an inorganic base compound to obtain the compound represented by formula B4, and the compound represented by formula B4 is reacted under a phosphorus catalyst to obtain the compound represented by formula B5; In method three, the cyano group of the compound represented by formula A5 reacts in the presence of hydrogen and a precious metal catalyst to obtain an amine-containing compound represented by formula C2, and the compound represented by formula C2 reacts with an amine compound to prepare the diketone compound, or the compound represented by formula C2 reacts with a carboxylic acid compound to prepare the diketone compound.

[0023] Furthermore, the specific preparation method of the diketone compound described in method 1 is as follows: Step 1: dissolving a substituted amine compound represented by formula A1 in a mixture of concentrated hydrochloric acid and water, and adding a diazotizing agent solution under an ice bath; then adding an aqueous solution of N-cyanourea A2 and sodium acetate to the reaction solution, and obtaining a compound represented by formula A3 after the reaction is complete; Step 2: dissolving the compound represented by formula A3 and a base in an acid and refluxing at high temperature to cause a ring-closing reaction, and after the reaction is complete, obtaining the compound represented by formula A4; Step 3: dissolving the compound represented by formula A4 in an organic solvent, and reacting it with a halogenated hydrocarbon under alkaline conditions to obtain a compound represented by formula A5; Step 4: Carboxylating the compound represented by formula A5 under at least one of acetic acid, concentrated hydrochloric acid and sulfuric acid to obtain a compound represented by formula A6 containing carboxylic acid; Step 5: Under nitrogen protection, the compound represented by formula A6 is subjected to chlorination reaction with at least one of oxalyl chloride, thionyl chloride, phosphorus trichloride or phosphorus pentachloride in the presence of a catalyst to obtain a compound represented by formula A7 after complete reaction.

[0024] Step 6: react the compound represented by formula 7 with an amine compound to obtain a compound represented by formula A.

[0025] In one embodiment of the present invention, in step 1, the diazotization reagent in the diazotization reagent solution is selected from one or more of sodium nitrite, tert-butyl nitrite, isopentyl nitrite, nitrosylsulfuric acid and nitrosate tetrafluoroborate.

[0026] Furthermore, the reagent of the diazotization reagent solution is one or more of aqueous sulfuric acid, hydrochloric acid, hydrobromic acid, glacial acetic acid, acetone, tetrahydrofuran, and toluene.

[0027] In one embodiment of the present invention, in step 1, the reaction conditions are: reaction temperature -5°C to 5°C, and reaction time is 2 to 4 hours.

[0028] In one embodiment of the present invention, in step 2, the conditions of the ring-closure reaction are: reaction temperature 90°C-120°C, reaction time 4-8h.

[0029] In one embodiment of the present invention, in step 2, the base is selected from one or more of sodium acetate, potassium carbonate, potassium acetate, sodium carbonate, triethylamine and DIPEA.

[0030] In one embodiment of the present invention, in step 2, the acid is selected from one or more of glacial acetic acid, formic acid, methanesulfonic acid and trifluoroacetic acid.

[0031] In one embodiment of the present invention, in step 3, the reaction temperature is 10°C to 40°C, and the reaction time is 6 h to 12 h.

[0032] In one embodiment of the present invention, in step 3, the organic solvent is selected from one or more of acetonitrile, acetone, DMF, tetrahydrofuran, ethanol and DMSO.

[0033] In one embodiment of the present invention, in step 3, the pH value of the alkaline condition is 7-11.

[0034] In one embodiment of the present invention, in step 5, the catalyst in the acyl chlorination reaction is DMF; the reaction solvent is DCM and acetonitrile; and the reaction time is 10-40°C.

[0035] In one embodiment of the present invention, in step 6, the reaction conditions are: the base used is selected from triethylamine or DIPEA, the solvent used is one or more of DCM, DMF and DCE, and the reaction temperature is -10°C to 10°C.

[0036] Furthermore, in the preparation method of diketone compounds described in method 2, the copper salt catalyst is an organic copper salt catalyst, the base catalyst is an organic base catalyst, the inorganic base compound is an alkali metal carbonate, and the phosphorus catalyst is an inorganic phosphorus compound.

[0037] Furthermore, in the method for preparing diketone compounds described in method 2, the noble metal catalyst is a palladium catalyst, and the carboxylic acid compound includes 1-methylpiperidine-4-carboxylic acid.

[0038] The third object of the present invention is to provide the use of the diketone compound and its isomers or pharmaceutically acceptable salts or hydrates in the preparation of malignant tumor drugs or in the preparation of eukaryotic elongation factor kinase 2 (eEF2K) inhibitors. Malignant tumor drugs refer to drugs for treating malignant tumors.

[0039] In one embodiment of the present invention, the malignant tumor is selected from breast cancer, colon cancer, lung cancer, esophageal cancer, breast cancer, etc.

[0040] The present invention discloses an anti-tumor drug, the active ingredient of which includes the above-mentioned diketone compound and its isomer or pharmaceutically acceptable salt or hydrate. The diketone compound of the present invention can be used as the active ingredient of the anti-tumor drug alone or in combination with other drugs as the active ingredient of the anti-tumor drug.

[0041] The above technical solution of the present invention has the following advantages compared with the prior art: The present invention designs and synthesizes compounds having a structure of general formula A and finds that such compounds exhibit strong binding ability and in vitro cell inhibition activity to eEF2K and have good selectivity. The present invention reveals and illustrates the relationship between the structure and activity of such compounds in a wider range, in a more in-depth and comprehensive manner, and has more important application value.

[0042] The present invention designs a diketone compound having a structure of the general formula A and finds that the compound having such a structure has a strong affinity for eEF2K and exhibits a strong anti-malignant tumor cell activity, and has low toxicity to normal cells and good safety. The present invention discloses and illustrates the relationship between the structure and activity of diketone compounds in a wider range and in a more in-depth and comprehensive manner, and has important application value. The diketone compounds of the present invention can have a good therapeutic effect on malignant tumors (such as triple-negative breast cancer) when acting on eEF2K. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] In order to make the content of the present invention more clearly understood, the present invention is further described in detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings, wherein: Figure 1 The figure is a schematic diagram of the synthesis of diketone compounds of the present invention.

[0044] Figure 2 Schematic diagram of the synthesis of compounds Z82 and Z83 described in the examples of the present invention.

[0045] Figure 3Schematic diagram of the synthesis of compounds Z86, Z87, Z88 and Z89 described in the examples of the present invention.

[0046] Figure 4 (A) is the inhibitory activity of Z19 and Z37 in Test Example 1 of the present invention on other breast cancer cells; (B) is the degradation effect of Z19 and Z37 in Test Example 3 of the present invention on eEF2K protein; (C) is the SPR binding experiment diagram of representative compounds in the embodiments of the present invention and eEF2K protein.

[0047] Figure 5 (A) and (B) are the in vivo anti-tumor effects of Z19 in Test Example 4 of the present invention; (C) and (D) are the effects of Z19 on mouse body weight and major organs in Test Example 4 of the present invention. DETAILED DESCRIPTION

[0048] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0049] In the following examples of the present invention, the structures of the compounds are determined by nuclear magnetic resonance (NMR) or mass spectrometry (MS). NMR is measured using an Agilent 300 MHz or 600 MHz instrument, and the measurement solvent is deuterated dimethyl sulfoxide (DMSO- d 6 ), deuterated chloroform (CDCl 3 ), tetramethylsilane (TMS) as internal standard, MS was performed with GCT Premier TM (CI) Measured by mass spectrometer, all sources were CI (70 eV) unless otherwise specified.

[0050] Thin layer chromatography silica gel plates use Yantai Huanghai HSGZ534 or Qingdao GZ534 silica gel plates. The specifications of the silica gel plates used in thin layer chromatography (TLC) are 0.15mm-0.2mm. Column chromatography generally uses Yantai Huanghai 100-200 mesh or 200-300 mesh silica gel as the carrier.

[0051] Unless otherwise specified, the reaction condition of nitrogen filling means that the reaction bottle is connected to a nitrogen balloon with a volume of about 1L, and the reaction condition is room temperature (rt), and the temperature range is 20-30℃.

[0052] In the following examples of the present invention, all solvents were redistilled before use, and the anhydrous solvents used were obtained by drying according to standard methods.

[0053] Figure 1 , Figure 2 as well as Figure 3The following is a schematic diagram of the synthesis of diketone compounds of the present invention. The following experiments illustrate the technical progress of the present invention, and the structural formula of the prepared compound is shown above. The raw materials used in the present invention are all conventional products, and the specific preparation operations and performance tests are conventional techniques. The animal experiments used meet the relevant requirements of Soochow University, and the statistical analysis is a conventional method.

[0054] Example 1

[0055] This example provides the synthesis of the compound, and the schematic diagram is shown below. Taking compound Z1(2-263) as an example, the specific preparation method is as follows. Among them, the reaction conditions are: (a) NaNO 2 , HCl, AcONa, pyridine, 0℃; (b) AcONa, AcOH, 110℃; (c) K 2 CO 3 , acetonitrile; (d) HCl, AcOH, 110 °C; (e) oxalyl chloride, DMF, DCM, N 2 ; (f) Et 3 N, DCM, 0°C.

[0056] (1) Synthesis of compound Z1C: 5 g (41.26 mmol) of 3,4-dimethylaniline (Z1A) was placed in a 250 mL round-bottom flask, and 60 mL of water and 22.5 mL of concentrated hydrochloric acid were added. The solution was placed in an ice bath and stirred to cool down, and then 3.94 g (57.76 mmol) of sodium nitrite was dissolved in 20 mL of water and slowly added to the previous solution, and TLC was detected. After the reaction of 3,4-dimethylaniline was complete, 6.7 g (41.26 mmol) of N-cyanoacetyl urethane (Z1-B) and 10 g (123.78 mmol) of sodium acetate were dissolved in 50 mL of a mixture of pyridine: water (1:1 (v / v)), and then dropped into the diazonium salt solution under an ice bath. After the reaction was completed, the mixture was filtered, washed with water 3 times, and dried to obtain 10.04 g of a yellow solid with a yield of 84.44%. NMR data of the product: 1 H NMR (300 MHz, DMSO- d 6 ) d 11.95 (s, 1H),10.42 (d, J = 4.5 Hz, 1H), 7.50 – 7.35 (m, 2H), 7.11 (d, J = 7.9 Hz, 1H),4.15 (tt, J = 7.7, 4.7 Hz, 2H), 2.18 (d, J= 11.3 Hz, 6H), 1.41 – 1.16 (m,3H).

[0057] (2) Synthesis of compound Z1D: Place 10.04 g (34.82 mmol) of Z1C and 14.28 g (174.12 mmol) of sodium acetate in a 250 mL round-bottom flask, dissolve with 120 mL of glacial acetic acid, and reflux at 110°C. After the reaction is completed, add a large amount of water until no solid precipitates, filter, wash with water three times, and dry to obtain 7.8 g of light yellow solid with a yield of 92.46%. NMR data of the product: 1 H NMR (300MHz, CDCl 3 ) δ 9.31 (s, 1H), 7.32 (dd, J = 10.7, 5.0 Hz, 3H), 2.40 (s, 6H).

[0058] (3) Synthesis of compound Z1E 1.68 g (6.94 mmol) of Z1D and 1.92 g (13.87 mmol) of potassium carbonate were placed in a 250 mL round-bottom flask, 70 mL of acetonitrile was added and stirred in an ice bath, and benzyl bromide was slowly added dropwise. After the reaction was completed, extraction was performed, the mixture was washed with a saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10:1 (v / v)) to obtain 1.99 g of a white solid with a yield of 86.33%. NMR data of the product: 1 H NMR (300 MHz, CDCl3) δ 7.62 – 7.49 (m,2H), 7.34 (q, J = 2.8 Hz, 3H), 7.26 – 7.13 (m, 3H), 5.16 (s, 2H), 2.31 (s, 6H).

[0059] (4) Synthesis of compound Z1F Dissolve 1.5 g (4.52 mmol) of compound Z1E in 32 mL of glacial acetic acid, heat and stir, heat to 70°C, add 16 mL of concentrated hydrochloric acid, and reflux at 110°C. After the reaction is completed, evaporate the glacial acetic acid under reduced pressure, wash the remaining solid with water once, dissolve it in ether and stir until a white solid precipitates, collect the solid by suction and obtain 1.1 g of white solid, with a yield of 69.37%.

[0060] (5) Synthesis of compound Z1G Place 100 mg (300.88 μmol) of compound Z1F in a two-necked bottle under nitrogen protection. Inject 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and inject into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0061] (6) Synthesis of compound Z1 3-Piperidinecarboxamide (237.17 μmol) was dissolved in redistilled DCM and Et 3 N (474.35 μmol) was placed in an ice bath and stirred. Z1G was then diluted with DCM and added dropwise to the reaction solution. After the reaction was completed, it was evaporated under reduced pressure and purified by chromatography (DCM: MeOH = 80: 1 (v / v)) to obtain 49 mg of a white solid with a yield of 44.76%. The NMR data of the product: 1 H NMR (300 MHz, CDCl 3 ) d 7.37 (q, J = 8.9, 8.2 Hz, 3H), 7.22 (d, J = 8.0 Hz, 4H), 6.98 (d, J = 8.1 Hz, 2H), 6.83 (t, J = 7.3 Hz, 1H), 5.03 (s, 2H), 3.72 (s, 4H), 3.14 (d, J = 19.4 Hz, 4H), 2.25 (s, 6H).

[0062]

[0063] Example 2 This example provides the synthesis of compound Z2, which is as follows: The synthesis method of compound Z2 refers to the synthesis method of Z1, except that 3-piperidinecarboxamide is replaced by N-phenylpiperazine. The NMR data of the product: 1 H NMR (300 MHz, CDCl 3 ) d 7.27 (dt, J = 33.8, 10.1 Hz, 10H), 6.95 (d, J = 8.1 Hz, 2H), 6.80(t, J = 7.3 Hz, 1H), 5.00 (s, 2H), 3.69 (s, 4H), 3.12 (d, J= 19.8 Hz, 4H), 2.23 (s, 6H).

[0064] Example 3 This example provides a method for synthesizing compound Z3, which is as follows: The method for synthesizing compound Z3 refers to the method for synthesizing compound Z1, except that 3-piperidinamide is replaced by o-methoxybenzylamine. The NMR data of the product: 1 H NMR (300 MHz, CDCl 3 ) d 9.22 (s, 1H), 7.62 – 7.49 (m, 2H), 7.42 – 7.21 (m, 8H), 6.94 (d, J = 8.8 Hz, 2H), 5.22 (s, 2H), 4.69 (d, J = 5.9 Hz, 2H), 3.95 (s, 3H), 2.32 (s, 6H).

[0065] Example 4 This example provides a method for synthesizing compound Z4, which is as follows: The method for synthesizing compound Z4 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by N-ethylpiperazine. The NMR data of the product: 1 H NMR (300MHz, CDCl 3 ) d 7.70 – 7.56 (m, 2H), 7.42 – 7.24 (m, 6H), 5.23 (t, J = 3.5 Hz,2H), 3.86 (t, J = 5.0 Hz, 2H), 3.50 (q, J = 4.7 Hz, 2H), 2.66 – 2.47 (m, 6H), 2.35 (q, J = 3.1, 2.3 Hz, 6H), 1.17 (td, J = 6.8, 3.5 Hz, 3H).

[0066] Example 5 This example provides a method for synthesizing compound Z5, which is as follows: The method for synthesizing compound Z5 refers to the method for synthesizing compound Z1, except that 3-piperidinamide is replaced by N-(2-aminoethyl)pyrrole. The NMR data of the product: 1 H NMR (300 MHz, CDCl 3 ) d 8.84 (t,J = 5.4 Hz, 1H), 7.53 (dd, J = 6.8, 2.8 Hz, 2H),7.33 (dd, J = 5.2, 2.0 Hz, 3H), 7.27 – 7.16 (m, 3H), 5.19 (s, 2H), 3.64 (q, J = 6.2 Hz, 2H), 2.87 – 2.63 (m, 6H), 2.28 (s, 6H), 1.85 (d, J = 3.8 Hz, 4H).

[0067] Example 6 This example provides a method for synthesizing compound Z6, which is as follows: The method for synthesizing compound Z6 refers to the method for synthesizing compound Z1, except that 3-piperidinylcarboxamide is replaced by 4-morpholinemethylaniline. The NMR data of the product: 1 H NMR (300 MHz, CDCl 3 ) d 10.81 (s, 1H), 7.79 – 7.37 (m, 8H), 7.29 (d, J = 8.3 Hz,4H), 5.29 (s, 2H), 3.76 (s, 4H), 3.53 (s, 2H), 2.49 (s, 4H), 2.36 – 2.24 (m,6H).

[0068] Example 7 This example provides a method for synthesizing compound Z7, which is as follows: The method for synthesizing compound Z7 is based on the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by 4-amino-1-benzylpiperidine. The NMR data of the product: 1 HNMR (300 MHz, CDCl3) d 8.69 (s, 1H), 7.53 (s, 2H), 7.32 (s, 8H), 7.21 (s,3H), 5.19 (s, 2H), 4.02 (s, 1H), 3.52 (s, 2H), 2.80 (s, 2H), 2.28 (d, J = 3.6Hz, 6H), 2.20 (s, 2H), 2.00 (s, 2H), 1.26 (s, 2H).

[0069] Example 8 This example provides a method for synthesizing compound Z8, which is as follows: The method for synthesizing compound Z8 is based on the method for synthesizing compound Z1, except that 3-piperidinamide is replaced by 4-aminobenzoic acid methyl ester. The NMR data of the product: 1 H NMR (300 MHz, DMSO- d 6 ) δ 10.95 (s, 1H), 7.97 (d, J = 7.6 Hz, 2H), 7.80 (d, J =8.4 Hz, 2H), 7.52 – 7.18 (m, 8H), 5.07 (s, 2H), 3.83 (s, 3H), 2.26 (s, 6H).

[0070] Example 9 This example provides a method for synthesizing compound Z9, which is as follows: The method for synthesizing compound Z9 refers to the method for synthesizing compound Z1, except that 3-piperidinamide is replaced by β-alanine methyl ester hydrochloride. The NMR data of the product: 1 HNMR (300 MHz, DMSO- d 6 ) δ 8.80 (s, 1H), 7.43 – 7.19 (m, 8H), 5.03 (s, 2H), 3.61 (d, J = 5.1 Hz, 3H), 3.48 (q, J = 6.5 Hz, 2H), 2.57 (t, J = 6.7 Hz, 2H),2.27 (s, 6H).

[0071] Example 10 This example provides a method for synthesizing compound Z10.

[0072] (1) Synthesis of compound Z10A The synthesis method of compound Z10A refers to the synthesis method of Z1, except that 3-piperidinamide is replaced by 2-bromoethylamine hydrobromide. NMR data of the product: 1 H NMR (300 MHz, CDCl3) d 9.10 (s, 1H), 7.56 (s, 2H), 7.42 – 7.28 (m, 3H), 7.25 (d, J = 10.5 Hz, 3H), 5.28 – 5.17 (m, 2H), 3.90 (d, J= 6.8 Hz, 2H), 3.58 (d, J = 5.7 Hz, 2H), 2.38 – 2.22 (m, 6H).

[0073] (2) Synthesis of compound Z10 Dissolve 50 mg (109.3 μmol) of compound Z10A in 3 mL of acetonitrile, add 71.24 mg (218.60 μmol) of cesium carbonate, and stir under reflux at room temperature. After the reaction is completed, evaporate under reduced pressure and purify by chromatography column (DCM: MeOH = 80: 1) to obtain 18 mg of white solid with a yield of 43.74%. 1 H NMR (300 MHz, CDCl 3 ) d 7.52 (d, J = 6.0 Hz, 2H),7.25 (s, 3H), 7.14 (s, 3H), 5.14 (s, 2H), 4.35 (t, J = 9.7 Hz, 2H), 4.11 (t, J = 9.8 Hz, 2H), 2.22 (s, 6H).

[0074] Embodiment 11 This example provides the synthesis of the compound, and the schematic diagram is shown below. Taking compound Z11 as an example, the specific preparation method is as follows. Wherein, the reaction conditions (a) K 2 CO 3 , iodomethane, acetonitrile, rt; (b) HCl, glacial acetic acid, 110 °C; (c) oxalyl chloride, DCM, DMF, N 2 , rt; (d) piperidine, Et 3 N, DCM, 0°C.

[0075] (1) Synthesis of compound Z11-A Compound Z1-D (Z1D) 400 mg (1.65 mmol) and potassium carbonate 456.43 mg (3.30 mmol) were placed in a 100 mL round-bottom flask, 20 mL of acetonitrile was added and stirred in an ice bath, and iodomethane was slowly added dropwise. After the reaction was completed, extraction was performed, washing with saturated NaCl solution, drying with anhydrous sodium sulfate, evaporation under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10: 1) to obtain 220 mg of white solid with a yield of 51.99%.

[0076] (2) Synthesis of compound Z11-B Dissolve 220 mg (858.49 μmol) of Z11-A in 10 mL of glacial acetic acid, heat and stir, heat to 70°C, add 5 mL of concentrated hydrochloric acid, and reflux at 110°C. After the reaction is completed, evaporate the glacial acetic acid under reduced pressure, wash the remaining solid with water once, dissolve it in ether and stir until a white solid precipitates, collect the solid by suction and obtain 204 mg of a white solid, with a yield of 86.33%.

[0077] (3) Synthesis of compound Z11-C Place 204 mg (741.11 μmol) of compound Z11-B in a two-necked bottle under nitrogen protection. Inject 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and inject into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0078] (4) Synthesis of compound Z11 Piperidine (741.11 μmol) was dissolved in redistilled DCM and Et 3 N (1.48 mmol) was placed in an ice bath and stirred. Compound Z11-C was then diluted with DCM and added dropwise to the reaction solution. After the reaction was completed, the mixture was evaporated under reduced pressure and purified by chromatography (PE:EA=3:1) to obtain 170 mg of a white solid with a yield of 57.28%. 1 H NMR (500 MHz, CDCl 3 ) δ 7.59 (dd, J = 7.9,2.2 Hz, 1H), 7.41 (d, J = 2.1 Hz, 1H), 7.17 (dq, J = 8.0, 1.0 Hz, 1H), 3.62 –3.54 (m, 2H), 3.53 – 3.45 (m, 2H), 3.45 (s, 3H), 2.28 (d, J = 1.1 Hz, 3H), 2.23 (s, 2H), 1.78 – 1.68 (m, 6H).

[0079]

[0080] Example 12 Taking compound Z12 as an example, the specific preparation method is as follows. Among them, the reaction conditions (a) K 2 CO 3 , acetonitrile, 3-fluorobenzyl bromide; (b) HCl, glacial acetic acid, 110 °C; (c) oxalyl chloride, DCM, DMF, N 2, rt; (d) N-(propyl-2-yn-1-yl)piperidine-3-carboxamide, Et 3 N, DCM, 0°C.

[0081] (1) Synthesis of compound Z12-A Compound Z1-D 1.68g (6.94mmol) and potassium carbonate 1.92g (13.87mmol) were placed in a 250mL round-bottom flask, 70mL acetonitrile was added and stirred in an ice bath, and 3-fluorobenzyl bromide was slowly added dropwise. After the reaction was completed, extraction was performed, the product was washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE:EA = 10:1) to obtain 1.90g of white solid with a yield of 78.20%.

[0082] (2) Synthesis of compound Z12-B Dissolve 1.5 g (4.06 mmol) of Z12-A in 32 mL of glacial acetic acid, heat and stir, heat to 70°C, add 16 mL of concentrated hydrochloric acid, and reflux at 110°C. After the reaction is completed, evaporate the glacial acetic acid under reduced pressure, wash the remaining solid with water once, dissolve it in ether and stir until a white solid precipitates, collect the solid by suction and obtain 1.1 g of white solid, with a yield of 69.56%.

[0083] (3) Synthesis of compound Z12-C Place 100 mg (270.74 μmol) of intermediate Z12-B in a two-necked bottle under nitrogen protection. Inject 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and inject into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0084] (4) Synthesis of compound Z12 The synthesis method of compound Z12 is the same as that of Z1(2-263), except that 3-piperidinecarboxamide is replaced by N-(propyl-2-yn-1-yl)piperidine-3-carboxamide, and Z1-G is replaced by Z12-C. 1 H NMR (500 MHz, CDCl 3 ) δ 7.59(dd, J = 7.9, 2.2 Hz, 1H), 7.44 – 7.39 (m, 2H), 7.34 (td, J = 8.0, 5.0 Hz,1H), 7.17 (dq, J = 8.0, 1.0 Hz, 1H), 7.12 (ddtd, J = 7.8, 2.9, 1.9, 0.9 Hz,2H), 7.03 (tdd,J = 7.9, 1.9, 1.2 Hz, 1H), 5.06 (s, 2H), 3.97 – 3.86 (m, 2H), 3.84 (dd, J = 12.4, 4.9 Hz, 1H), 3.65 – 3.57 (m, 2H), 3.60 – 3.53 (m, 1H), 2.60 (tt, J = 6.0, 4.8 Hz, 1H), 2.33 (t, J = 3.0 Hz, 1H), 2.28 (d, J = 1.1Hz, 3H), 2.23 (s, 1H), 1.89 – 1.71 (m, 3H), 1.74 – 1.64 (m, 1H).

[0085] Embodiment 13

[0086] This example provides a method for synthesizing compound Z13. Compound Z1-E (Z1E, 100 mg 300.88 mmol) was dissolved in 2 mL of ethanol and stirred at 0°C, 6 mg NaOH and 17.47 mg DMSO were added, and the reaction was allowed to proceed overnight. After the reaction was completed, the ethanol was evaporated under reduced pressure, and the mixture was dissolved in DCM and washed with water 2 to 3 times, washed once with a saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The solid was purified by chromatography to obtain 50 mg of a white solid with a yield of 47.43%. NMR data of the product: 1 H NMR (300 MHz, CDCl 3 ) d 8.43 (s, 1H), 7.50 – 7.44 (m, 2H), 7.30 – 7.25 (m, 3H), 7.19 (d, J =2.1 Hz, 3H), 5.92 (s, 1H), 5.15 (s, 2H), 2.22 (d, J = 3.2 Hz, 6H).

[0087] Embodiment 14

[0088] This example provides a method for synthesizing compound Z14, which is as follows: The method for synthesizing compound Z14 refers to the method for synthesizing compound Z1, except that 3-piperidinylcarboxamide is replaced by dimethylamine hydrochloride, and the NMR data of the product is: 1 H NMR (300 MHz, Chloroform- d) δ 7.56 (s, 2H), 7.37 – 7.30 (m, 3H), 7.23 (d, J =11.3 Hz, 3H), 5.19 (d, J = 3.2 Hz, 2H), 3.12 (d, J = 2.5 Hz, 3H), 3.03 (d, J = 2.6 Hz, 3H), 2.30 (s, 6H).

[0089] Embodiment 15

[0090] Taking compound Z15 as an example, the specific preparation method is as follows. Among them, the reaction conditions (a) K 2 CO 3 , iodomethane, acetonitrile, rt; (b) HCl, glacial acetic acid, 110 °C; (c) oxalyl chloride, DCM, DMF, N 2 , rt; (d) 3-piperidinic acid ethyl ester, Et 3 N, DCM, 0°C.

[0091] (1) Synthesis of compound Z15-A Compound Z1-D (Z1D, 400 mg 1.65 mmol) and potassium carbonate 456.43 mg (3.30 mmol) were placed in a 100 mL round-bottom flask, 20 mL acetonitrile was added and stirred in an ice bath, and iodomethane was slowly added dropwise. After the reaction was completed, extraction was performed, washing with saturated NaCl solution, drying with anhydrous sodium sulfate, evaporation under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10: 1) to obtain 220 mg of white solid with a yield of 51.99%.

[0092] (2) Synthesis of compound Z15-B Dissolve 220 mg (858.49 μmol) of Z15-A in 10 mL of glacial acetic acid, heat and stir, heat to 70°C, add 5 mL of concentrated hydrochloric acid, and reflux at 110°C. After the reaction is completed, evaporate the glacial acetic acid under reduced pressure, wash the remaining solid with water once, dissolve it in ether and stir until a white solid precipitates, collect the solid by suction and obtain 204 mg of a white solid, with a yield of 86.33%.

[0093] (3) Synthesis of compound Z15-C Place 204 mg (741.11 μmol) of compound Z15-B in a two-necked bottle under nitrogen protection. Inject 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and inject into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0094] (4) Synthesis of compound Z15 Piperidine (741.11 μmol) was dissolved in redistilled DCM, Et3N (1.48 mmol) was added, and the mixture was stirred in an ice bath. Compound Z11-C was then diluted with DCM and added dropwise to the reaction solution. After the reaction was completed, the mixture was evaporated under reduced pressure and purified by chromatography (PE:EA=2:1) ​​to obtain 170 mg of a white solid with a yield of 57.28%. The NMR data of the product were as follows: 1 H NMR (300 MHz, CDCl 3 ) δ 7.29 –7.17 (m, 4H), 7.11 (d, J = 10.6 Hz, 2H), 6.86 (s, 1H), 5.15 (d, J = 8.7 Hz,2H), 3.85 – 3.74 (m, 3H), 3.70 (s, 2H), 3.35 (s, 2H), 2.30 (d, J = 7.8 Hz,6H), 1.65 (d, J = 14.0 Hz, 6H).

[0095] Example 16

[0096] This example provides a method for synthesizing compound Z16, which is as follows: The method for synthesizing compound Z16 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by piperidine, and the NMR data of the product is: 1 H NMR (300 MHz, CDCl 3 ) δ 7.37-7.16 (m, 6H), 7.01 (s, 1H), 5.15 (d, J = 4.4 Hz, 2H), 3.70 (d, J = 5.9 Hz, 2H), 3.35 (t, J = 5.2 Hz, 2H), 2.29 (d, J = 4.4 Hz, 6H), 1.65 (d, J = 18.4 Hz, 6H).

[0097] Embodiment 17 Taking compound Z17 as an example, the specific preparation method is as follows. Wherein, reaction conditions (a) K 2 CO 3 , acetonitrile, 3-methylbenzyl bromide; (b) HCl, glacial acetic acid, 110°C; (c) oxalyl chloride, DCM, DMF, N 2 , rt; (d) piperidine, Et3 N, DCM, 0°C.

[0098] (1) Synthesis of compound Z17-A Compound Z1-D (Z1D, 500 mg 2.06 mmol) and potassium carbonate 458.39 mg (2.48 mmol) were placed in a 100 mL round-bottom flask, 30 mL acetonitrile was added and stirred in an ice bath, and 3-methylbenzyl bromide was slowly added dropwise. After the reaction was completed, extraction was performed, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10: 1) to obtain 538 mg of white solid with a yield of 75.25%.

[0099] (2) Synthesis of compound Z17-B Dissolve 538 mg (1.55 mmol) of compound Z17-A in 10 mL of glacial acetic acid, heat and stir, heat to 70°C, add 5 mL of concentrated hydrochloric acid, and reflux at 110°C. After the reaction is completed, evaporate the glacial acetic acid under reduced pressure, wash the remaining solid with water once, dissolve it in ether and stir until a white solid precipitates, collect the solid by suction and obtain 400 mg of a white solid with a yield of 70.48%.

[0100] (3) Synthesis of compound Z17-C Place 200 mg (547.42 μmol) of compound Z17-B in a two-necked bottle under nitrogen protection. Inject 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and inject into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0101] (4) Synthesis of compound Z17 The synthesis method of compound Z17 refers to the synthesis method of Z1, except that 3-piperidinecarboxamide is replaced by piperidine, and Z1-G is replaced by Z17-C. The NMR data of the product are: 1 H NMR (500 MHz, CDCl 3 ) δ 7.59 (dd, J =7.9, 2.2 Hz, 1H), 7.41 (d, J = 2.1 Hz, 1H), 7.17 (dt, J = 8.1, 1.0 Hz, 3H),7.11 (dq, J = 7.2, 0.8 Hz, 2H), 5.06 (t, J= 1.0 Hz, 2H), 3.63 – 3.56 (m,1H), 3.60 – 3.53 (m, 1H), 3.53 – 3.45 (m, 2H), 2.34 (s, 2H), 2.28 (d, J = 1.1Hz, 3H), 2.23 (s, 2H), 1.78 – 1.67 (m, 6H).

[0102] Embodiment 18 This example provides a method for synthesizing compound Z18, which is as follows: The method for synthesizing compound Z18 is based on the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by 4,4-difluoropiperidine. The NMR data of the product: 1 H NMR (400 MHz, CDCl 3 ) d 7.57 – 7.51 (m, 2H), 7.33 (dd, J = 5.0, 2.0 Hz, 3H), 7.22– 7.20 (m, 1H), 7.18 (dd, J = 7.8, 5.6 Hz, 2H), 5.17 (s, 2H), 3.92 – 3.81 (m,2H), 3.50 (dd, J = 6.9, 4.8 Hz, 2H), 2.29 (s, 6H), 2.15 – 1.98 (m, 4H).

[0103] Embodiment 19

[0104] This embodiment provides a method for synthesizing compound Z19, which is as follows: The method for synthesizing compound Z19 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by piperidine. 1 H NMR (300 MHz, CDCl 3 ) d 7.58(qd, J = 3.6, 2.0 Hz, 2H), 7.40 – 7.26 (m, 4H), 7.22 (d, J = 1.7 Hz, 2H),5.19 (d, J = 1.5 Hz, 2H), 3.73 (d, J = 5.4 Hz, 2H), 3.37 (t, J= 5.3 Hz, 2H), 2.31 (s, 6H), 1.79 – 1.62 (m, 6H).

[0105] Embodiment 20

[0106] This example provides a method for synthesizing compound Z20, which is as follows: The method for synthesizing compound Z20 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by morpholine. 1 H NMR (300 MHz, CDCl 3 ) δ 7.54(d, J = 5.7 Hz, 2H), 7.32 (dd, J = 4.9, 2.4 Hz, 2H), 7.26 (t, J = 2.8 Hz,2H), 7.19 (d, J = 2.6 Hz, 2H), 5.20 – 5.13 (m, 2H), 3.78 (d, J = 2.6 Hz, 4H),3.70 (d, J = 5.2 Hz, 2H), 3.48 – 3.38 (m, 2H), 2.29 (t, J = 2.7 Hz, 6H).

[0107] Embodiment 21

[0108] This example provides a method for synthesizing compound Z21, which is as follows: The method for synthesizing compound Z21 is based on the method for synthesizing compound Z1, except that 3-piperidinamide is replaced by N-methyl-3-piperidinamide. The NMR data of the product: 1 H NMR (300 MHz, CDCl 3 ) d 7.52 (dq, J = 5.6, 3.1, 2.2 Hz, 2H), 7.31 (dd, J = 4.8, 2.6 Hz, 3H), 7.25 – 7.14 (m, 3H), 6.03 (d, J = 5.7 Hz, 1H), 5.15 (d, J = 4.7 Hz, 2H), 4.59 (d, J = 13.4 Hz, 1H), 4.38 (dd, J = 13.8, 3.9 Hz, 1H),3.66 (d,J = 13.4 Hz, 1H), 3.51 (d, J = 13.4 Hz, 1H), 3.38 – 2.66 (m, 6H), 2.49 – 2.36 (m, 1H), 2.28 (s, 6H), 2.08 – 1.74 (m, 3H).

[0109] Embodiment 22

[0110] This example provides a method for synthesizing compound Z22, which is as follows: The method for synthesizing compound Z22 refers to the method for synthesizing compound Z1, except that 3-piperidinamide is replaced by N,N-dimethyl 3-piperidinamide. The NMR data of the product: 1 H NMR (300 MHz, CDCl 3 ) d 7.52 (ddd, J = 15.1, 6.7, 3.2 Hz, 2H), 7.40 –7.29 (m, 3H), 7.25 – 7.14 (m, 3H), 5.16 (q, J = 7.3, 6.1 Hz, 2H), 4.72 (d, J = 12.7 Hz, 1H), 3.59 (t, J = 14.0 Hz, 1H), 3.40 (dd, J = 13.8, 10.8 Hz, 1H), 3.24 – 3.07 (m, 2H), 3.03 – 2.68 (m, 7H), 2.29 (d, J = 4.9 Hz, 6H), 2.08 –1.64 (m, 5H).

[0111] Embodiment 23

[0112] This embodiment provides a method for synthesizing compound Z23, which is as follows: wherein the reaction conditions (a) K 2 CO 3 , acetonitrile, 3-trifluoromethylbenzyl bromide; (b) HCl, glacial acetic acid, 110 °C; (c) oxalyl chloride, DCM, DMF, N 2 , rt; (d) 3-piperidinic acid ethyl ester, Et 3 N, DCM, 0°C.

[0113] (1) Synthesis of compound Z23-A Z1-D (Z1D, 600 mg 2.48 mmol), m-trifluoromethylbenzyl bromide 651.27 mg (2.72 mmol) and 684.64 mg potassium carbonate were placed in acetonitrile and stirred for 4 h. DCM / H 2 O extraction and recrystallization to obtain 670 mg of white solid with a yield of 67.56%. 1 H NMR (400 MHz, CDCl 3 ) δ 7.79 (d, J = 2.3 Hz, 1H), 7.74 (d, J = 7.7Hz, 1H), 7.61 (d, J = 7.8 Hz, 1H), 7.48 (t, J = 7.8 Hz, 1H), 7.24 (s, 1H), 7.22 – 7.15 (m, 2H), 5.21 (s, 2H), 2.31 (s, 6H).

[0114] (2) Synthesis of compound Z23-B Dissolve Z23-A (1.24 mmol) in 20 mL of acetic acid, add 4 mL of concentrated hydrochloric acid, and reflux at 100 °C for 4 h. After the reaction is completed, evaporate the acetic acid under reduced pressure, add ether and stir, and filter after all the solids are precipitated.

[0115] (3) Synthesis of compound Z23-C Compound Z23-B (100 mg) was dissolved in dichloromethane, and DMF and oxalyl chloride (60.35 mg) were added, and the mixture was stirred at room temperature and evaporated under reduced pressure and directly carried out to the next step.

[0116] (4) Synthesis of compound Z23 The synthesis method of compound Z23 refers to the synthesis method of Z1, except that 3-piperidinamide is replaced by Z23-C. NMR data of the product: 1 H NMR (300 MHz, DMSO- d 6 ) d 7.85 – 7.69 (m, 2H), 7.57 (d, J = 7.8 Hz, 1H), 7.45 (t, J = 7.7 Hz, 1H), 7.22 (d, J = 12.2 Hz, 3H), 5.08 (t, J= 1.0 Hz, 2H), 3.63 – 3.56 (m, 1H), 3.57 (dt, J = 4.5, 1.7 Hz, 1H), 3.53 –3.44 (m, 2H), 2.28 (d, J = 1.1 Hz, 3H), 2.23 (s, 2H), 1.78 – 1.67 (m, 6H).

[0117] Embodiment 24 This example provides a method for synthesizing compound Z24, which is as follows: The method for synthesizing compound Z24 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced by piperazine-1-carboxylic acid dimethylamine. NMR data of the product: 1 H NMR (300 MHz, CDCl 3 ) d 7.31 (t, J = 5.8 Hz, 2H), 7.28 –7.16 (m, 4H), 7.03 (dd, J = 9.4, 5.7 Hz, 1H), 5.31 (s, 1H), 5.16 (s, 2H), 3.79 (t, J = 4.9 Hz, 2H), 3.53 – 3.41 (m, 2H), 3.32 (dt, J = 14.3, 5.0 Hz, 4H), 2.87 (s, 6H), 2.30 (s, 6H).

[0118] Embodiment 25 This example provides a method for synthesizing compound Z25, which is as follows: The method for synthesizing compound Z25 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced by ethyl N-piperazinecarboxylate. NMR data of the product: 1 H NMR (300 MHz, Deuterium Oxide) d 7.36 – 7.26 (m, 3H), 7.20 (dd, J = 7.7, 4.7 Hz, 3H), 7.08 – 6.96 (m, 1H), 4.17 (q, J = 7.1 Hz, 2H), 3.84 –3.69 (m, 2H), 3.63 – 3.48 (m, 4H), 3.40 (dd,J = 6.7, 3.5 Hz, 2H), 2.29 (s,6H), 1.27 (t, J = 7.0 Hz, 3H).

[0119] Embodiment 26 This example provides a method for synthesizing compound Z26, which is as follows: The method for synthesizing compound Z26 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced by 1,4-diazacycloheptane-1-carboxylic acid tert-butyl ester. Product NMR data: 1 H NMR (300 MHz, Deuterium Oxide) d 7.36 – 7.26 (m,3H), 7.20 (dd, J = 7.7, 4.7 Hz, 3H), 7.08 – 6.96 (m, 1H), 4.17 (q, J = 7.1Hz, 2H), 3.84 – 3.69 (m, 2H), 3.63 – 3.48 (m, 4H), 3.40 (dd, J = 6.7, 3.5 Hz,2H), 2.29 (s, 6H), 1.27 (t, J = 7.0 Hz, 3H).

[0120] Embodiment 27 This example provides a method for synthesizing compound Z27, which is as follows: The method for synthesizing compound Z27 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced by 1-tert-butyloxycarbonylpiperazine. The NMR data of the product are: 1 H NMR (300 MHz, CDCl 3 ) d 7.31 (s, 2H), 7.26 – 7.14 (m, 4H), 7.00 (d, J = 9.4 Hz, 1H), 5.14 (s, 2H), 3.74 (t, J = 5.2 Hz, 2H), 3.57 – 3.34(m, 6H), 2.29 (s, 6H), 1.47 (s, 9H).

[0121] Embodiment 28 This example provides a method for synthesizing compound Z28, which is as follows: The method for synthesizing compound Z28 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced by 4,4-difluoropiperidine. The NMR data of the product are: 1 H NMR (300 MHz, CDCl 3 ) d -9.56 – -9.81 (m, 6H), -9.88 – -10.00 (m,1H), -11.79 (d, J = 3.5 Hz, 2H), -13.04 – -13.17 (m, 2H), -13.42 (dt, J =7.3, 4.0 Hz, 2H), -14.64 (d, J = 3.4 Hz, 6H), -14.88 (dq, J = 16.0, 9.3, 8.0 Hz, 4H).

[0122] Embodiment 29 This example provides a method for synthesizing compound Z29, which is as follows: The method for synthesizing compound Z29 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced by tetrahydropyrimidine-1(2H)-carboxylic acid tert-butyl ester. Product NMR data: 1 H NMR (300 MHz, CDCl 3 ) d 7.32 (d, J = 6.2 Hz, 2H), 7.22(d, J = 6.4 Hz, 3H), 7.02 (d, J = 8.5 Hz, 1H), 5.15 (s, 2H), 4.93 (s, 2H), 3.87 (t, J = 5.8 Hz, 2H), 3.61 (t, J = 5.7 Hz, 2H), 2.35 – 2.27 (m, 6H), 1.76 (s, 2H), 1.44 (s, 9H).

[0123] Embodiment 30 This embodiment provides a method for synthesizing compound Z30, which is as follows: The method for synthesizing compound Z30 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced by (S)-3-Boc-aminopiperidine.1 H NMR (300 MHz, CDCl 3 ) d 7.32 (d, J = 11.0 Hz, 4H), 7.25 (d, J = 10.2 Hz,3H), 7.04 (s, 1H), 5.18 (s, 2H), 4.90 (d, J = 35.2 Hz, 1H), 3.93 – 3.36 (m,2H), 3.36 – 3.10 (m, 1H), 2.31 (d, J = 2.9 Hz, 6H), 1.87 (d, J = 27.4 Hz, 4H), 1.49 (s, 3H), 1.41 (s, 6H).

[0124] Embodiment 31 This embodiment provides a method for synthesizing compound Z31, which is as follows: The method for synthesizing compound Z31 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced by (R)-3-Boc-aminopiperidine. 1 H NMR (300 MHz, CDCl3) δ 7.32 (d, J = 11.0 Hz, 4H), 7.25 (d, J = 10.2 Hz,3H), 7.04 (s, 1H), 5.18 (s, 2H), 4.90 (d, J = 35.2 Hz, 1H), 3.93 – 3.36 (m,2H), 3.36 – 3.10 (m, 1H), 2.31 (d, J = 2.9 Hz, 6H), 1.87 (d, J = 27.4 Hz, 4H), 1.49 (s, 3H), 1.41 (s, 6H).

[0125] Embodiment 32 This embodiment provides a method for preparing compound Z32, which is as follows: The synthesis method of compound Z32 refers to the synthesis method of Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced by 1-cyclopropylcarbonylpiperazine. 1 H NMR (300 MHz, CDCl 3 ) δ 7.30 (dd, J= 11.9, 3.5 Hz, 3H), 7.25 – 7.16 (m, 3H), 7.03(t, J = 8.6 Hz, 1H), 5.16 (s, 2H), 3.76 (d, J = 25.2 Hz, 6H), 3.45 (s, 2H), 2.31 (s, 6H), 1.74 (s, 1H), 1.02 (q, J = 4.0 Hz, 2H), 0.83 (d, J = 7.5 Hz, 2H).

[0126] Embodiment 33 This example provides a method for synthesizing compound Z33, which is as follows: The method for synthesizing compound Z33 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced by morpholine (237.17 μmol) and dissolved in redistilled DCM, and Et 3 N (434.19 μmol), placed in an ice bath and stirred. Then, the intermediate 22 was diluted with DCM and added dropwise to the reaction solution. After the reaction was completed, it was evaporated under reduced pressure and purified by chromatography column (PE: EA = 2:1) to obtain 102 mg of a white solid with a yield of 65.12%. The NMR data of the product: 1 H NMR (300 MHz, CDCl 3 ) d 7.30 (s, 2H), 7.23 (s, 4H), 7.00 (t, J = 8.2 Hz, 1H), 5.14 (s, 2H), 3.74 – 3.66 (m, 6H), 3.63 (dd, J =6.3, 3.5 Hz, 2H), 2.28 (s, 6H).

[0127] Embodiment 34 This example provides a method for synthesizing compound Z34, as follows: The method for synthesizing compound Z34 is based on the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced by tert-butyl 3,8-diazabicyclo[3.2.1]octane-3-carboxylate. The NMR data of the product are: 1 H NMR (300 MHz, CDCl 3 ) d 7.31 (s,2H), 7.19 (d, J = 11.3 Hz, 4H), 7.00 (d, J= 8.8 Hz, 1H), 5.14 (s, 2H), 4.80(s, 1H), 4.07 – 3.77 (m, 3H), 3.11 (dd, J = 31.5, 15.1 Hz, 2H), 2.29 (s, 6H), 2.00 (s, 2H), 1.87 – 1.73 (m, 2H), 1.45 (s, 9H).

[0128] Embodiment 35 This embodiment provides a method for synthesizing compound Z35, which is as follows: The method for synthesizing compound Z35 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced by 3-N-tert-butyloxycarbonylaminocyclobutylamine. 1 H NMR (300 MHz, CDCl 3 ) d 7.30 (d, J = 5.6 Hz, 2H), 7.26 – 7.13 (m,4H), 7.00 (td, J = 7.9, 6.6, 2.2 Hz, 1H), 5.12 (s, 3H), 4.48 (d, J = 10.5 Hz,3H), 4.14 – 4.03 (m, 1H), 3.99 (d, J = 7.7 Hz, 1H), 2.30 (s, 6H), 1.37 (s, 9H).

[0129] Embodiment 36 This example provides a method for synthesizing compound Z36, which is as follows: The method for synthesizing compound Z36 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced by azetidin-3-yl(methyl)carbamic acid tert-butyl ester. NMR data of the product: 1 H NMR (300 MHz, CDCl 3 ) d 7.39 – 7.28 (m, 3H),7.20 (d, J = 12.2 Hz, 3H), 7.02 (t, J = 8.3 Hz, 1H), 5.15 (s, 2H), 4.39 –4.31 (m, 2H), 4.26 (dd, J = 14.4, 6.0 Hz, 2H), 2.92 (d,J = 1.7 Hz, 3H), 2.31 (s, 6H), 1.46 (s, 9H).

[0130] Embodiment 37 This example provides a method for synthesizing compound Z37, which is as follows: The method for synthesizing compound Z37 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced by 3-Boc-aminomethylpiperidine. NMR data of the product: 1 H NMR (300 MHz, CDCl 3 ) d 7.33 – 7.24 (m, 3H), 7.23 – 7.17 (m, 3H), 7.02 (d, J = 8.3 Hz, 1H), 5.14 (s, 2H), 4.84 (s, 0.5H), 4.53 (s, 0.5H), 4.37 (d, J = 13.2 Hz, 0.5H), 4.13 (d, J = 13.2 Hz, 0.5H), 3.58 – 3.41 (m,1H), 3.20 (d, J = 9.2 Hz, 1H), 3.04 (dt, J = 23.6, 9.0 Hz, 3H), 2.29 (s, 6H), 1.79 (d, J = 19.1 Hz, 3H), 1.58 (s, 1H), 1.44 (s, 6H), 1.37 (s, 3H), 1.29 –1.16 (m, 1H).

[0131] Embodiment 38 This example provides a method for synthesizing compound Z38, which is as follows: The method for synthesizing compound Z38 is the same as that for Z15, except that piperidine is replaced by 3-Boc-aminomethylpiperidine. NMR data of the product: 1 H NMR (300 MHz, CDCl 3 ) δ 7.29 – 7.17 (m, 4H), 7.11 (d, J = 10.6 Hz, 2H), 6.86 (s, 1H), 5.15(d, J = 8.7 Hz, 2H) 4.37 (d, J = 13.2 Hz, 0.5H), 4.13 (d,J = 13.2 Hz, 0.5H), 3.85 – 3.74 (m, 3H), 3.58 – 3.41 (m, 1H), 3.20 (d, J = 9.2 Hz, 1H), 3.04 (dt, J = 23.6, 9.0 Hz, 3H), 2.29 (s, 6H), 1.79 (d, J = 19.1 Hz, 3H), 1.58 (s, 1H), 1.44 (s, 6H), 1.37 (s, 3H), 1.29 – 1.16 (m, 1H).

[0132] Embodiment 39 This example provides a method for synthesizing compound Z39, which is as follows: The synthesis of compound Z39 is the same as compound Z17, except that piperidine is replaced by 3-Boc-aminomethylpiperidine. Product NMR data: 1 H NMR (500 MHz, CDCl 3 ) δ 7.59 (dd, J = 7.9, 2.2 Hz, 1H), 7.41 (d, J = 2.2 Hz, 1H), 7.28 (ddq, J = 7.9, 2.2, 1.1 Hz, 1H), 7.21 – 7.14 (m, 2H), 7.12 (t, J = 2.1 Hz, 1H),7.13 – 7.04 (m, 1H), 5.09 – 4.99 (m, 2H), 4.91 (t, J = 6.3 Hz, 1H), 3.73 (dd, J = 12.5, 4.8 Hz, 1H), 3.61 – 3.48 (m, 2H), 3.47 (dd, J = 12.5, 4.8 Hz, 1H), 3.17 – 3.08 (m, 2H), 2.32 (d, J = 0.7 Hz, 3H), 2.28 (d, J = 1.1 Hz, 3H), 2.25(tt, J = 6.2, 4.9 Hz, 1H), 1.76 – 1.59 (m, 3H), 1.50 – 1.41 (m, 1H), 1.42 (s, 7H).

[0133] Embodiment 40 This example provides a method for synthesizing compound Z40, which is as follows: The synthesis of compound Z40 refers to compound Z12, except that N-propyl-2-yn-1-ylpiperidine-3-carboxamide is replaced with N-(oct-7-yn-1-yl)piperidine-3-carboxamide. NMR data of the product: 1 H NMR (300 MHz, CDCl 3 ) δ 7.27 (dt, J = 11.8, 5.5 Hz,6H), 7.01 (d, J = 8.2 Hz, 1H), 6.62 (t, J = 5.1 Hz, 1H), 5.14 (s, 2H), 4.72(dd, J = 13.4, 4.1 Hz, 0.5H), 4.42 – 4.34 (m, 0.5H), 4.16 – 3.97 (m, 2H), 3.74 (dd, J = 13.8, 4.1 Hz, 0.5H), 3.57 (d, J = 13.5 Hz, 0.5H), 3.37 (dd, J =13.7, 10.0 Hz, 0.5H), 3.18 – 2.96 (m, 1.5H), 2.63 (tt, J = 11.0, 5.1 Hz, 1H), 2.29 (s, 6H), 2.24 – 2.09 (m, 3H), 1.95 (d, J = 2.6 Hz, 1H), 1.87 – 1.71 (m,2H), 1.64 (td, J = 13.0, 12.3, 6.2 Hz, 4H), 1.37 (tdd, J = 24.5, 14.9, 7.8 Hz, 5H).

[0134] Embodiment 41 This embodiment provides a method for synthesizing compound Z41, which is as follows: The synthesis of compound Z41 refers to compound Z1, except that 3-piperidinecarboxamide is replaced by azetidine. 1 H NMR (300 MHz, CDCl 3 ) d 7.56(dd, J= 6.3, 3.0 Hz, 2H), 7.44 – 7.28 (m, 3H), 7.25 – 7.10 (m, 3H), 5.16 (s,2H), 4.22 (q, J = 8.2 Hz, 4H), 2.34 (d, J = 8.7 Hz, 2H), 2.29 (s, 6H).

[0135] Embodiment 42 This example provides a method for synthesizing compound Z42, which is as follows: The method for synthesizing compound Z42 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by N,N-dimethylethylenediamine. NMR data of the product: 1 H NMR (300 MHz, CDCl 3 ) d 8.80 (s, 1H), 7.65 – 7.15 (m, 9H), 5.20 (s, 2H), 3.57 (q, J = 6.0 Hz, 2H), 2.55 (t, J = 6.2 Hz, 2H), 2.30 (d, J = 8.9 Hz, 12H), 1.27(d, J = 8.9 Hz, 2H).

[0136] Embodiment 43 This embodiment provides a method for synthesizing compound Z43, which is as follows: The method for synthesizing compound Z43 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by N-(2-aminoethyl)morpholine. 1 H NMR (300 MHz, CDCl3) δ 8.97 (s, 1H), 7.54 (s, 2H), 7.34 (s, 4H), 7.22 (s, 2H), 5.21 (s,2H), 3.75 (s, 4H), 3.57 (s, 2H), 2.59 (s, 2H), 2.52 (s, 4H), 2.29 (d, J = 5.0Hz, 6H).

[0137] Embodiment 44 This example provides a method for synthesizing compound Z44, which is as follows: The method for synthesizing compound Z44 refers to the method for synthesizing compound Z1, except that 3-piperidinylcarboxamide is replaced by 2-pyridinemethylamine. NMR data of the product: 1H NMR (300MHz, CDCl 3 ) d 9.52 (s, 1H), 8.61 (s, 1H), 7.67 (s, 1H), 7.54 (s, 2H), 7.33 (s, 4H), 7.21 (s, 4H), 5.21 (d, J = 4.2 Hz, 2H), 4.79 (s, 2H), 2.28 (d, J =4.1 Hz, 6H).

[0138] Embodiment 45 This example provides a method for synthesizing compound Z45, which is as follows: The method for synthesizing compound Z45 refers to the method for synthesizing compound Z1, except that 3-piperidinamide is replaced by tetrahydropyrrole. The NMR data of the product: 1 H NMR (400MHz, CDCl 3 ) d 7.62 – 7.52 (m, 2H), 7.32 (dd, J = 5.1, 2.0 Hz, 3H), 7.22 (d, J = 1.9 Hz, 1H), 7.20 – 7.16 (m, 2H), 5.17 (s, 2H), 3.69 – 3.59 (m, 2H), 3.49 –3.41 (m, 2H), 2.28 (d, J = 1.7 Hz, 6H), 2.00 – 1.90 (m, 4H).

[0139] Embodiment 46 This example provides a method for synthesizing compound Z46, which is as follows: The synthesis of compound Z46 is based on compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced by 3-(methylsulfonyl)piperidine. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) d 7.59 (dd, J = 7.9, 2.2 Hz, 1H), 7.41 (d, J = 2.2 Hz, 1H), 7.34 (td, J = 8.0, 5.0 Hz, 1H), 7.17 (dq, J = 8.0, 1.0 Hz,1H), 7.12 (dddd,J = 8.2, 4.2, 2.0, 1.0 Hz, 3H), 7.03 (tdd, J = 7.9, 2.0, 1.2Hz, 1H), 5.06 (d, J = 1.8 Hz, 2H), 4.00 (dd, J = 12.3, 6.9 Hz, 1H), 3.88 (dd, J = 12.4, 6.9 Hz, 1H), 3.62 – 3.55 (m, 1H), 3.58 – 3.49 (m, 3H), 2.99 (d, J =1.5 Hz, 4H), 2.28 (d, J = 1.1 Hz, 3H), 2.23 (s, 3H), 2.09 – 1.97 (m, 2H), 1.92 – 1.68 (m, 4H).

[0140] Embodiment 47 This example provides a method for synthesizing compound Z47, which is specifically described below. The reaction conditions are: (a) NaNO 2 , HCl, AcONa, pyridine, 0℃; (b) AcONa, AcOH, 110℃; (c) K 2 CO 3 , acetonitrile; (d) HCl, AcOH, 110 °C; (e) oxalyl chloride, DMF, DCM, N 2 ; (f) piperidine, Et 3 N, DCM, 0°C.

[0141] (1) Synthesis of compound Z47B The synthesis of compound Z47B refers to compound Z1C, except that compound Z1A is replaced by compound Z47A. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 9.24 (s, 1H), 8.28 (dd, J = 4.3,1.6 Hz, 1H), 7.67 (td, J = 7.0, 1.7 Hz, 1H), 7.30 (dd, J = 7.0, 1.5 Hz, 1H),6.93 (ddd, J = 7.0, 4.2, 1.5 Hz, 1H), 4.21 (q, J= 6.4 Hz, 2H), 1.27 (t, J =6.2 Hz, 3H).

[0142] (2) Synthesis of compound Z47C The synthesis of compound Z47C was based on compound Z1D, except that compound Z1C was replaced by compound Z47B.

[0143] (3) Synthesis of compound Z47D The synthesis of compound Z47D refers to compound Z1E, except that compound Z1D is replaced by compound Z47-C. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 8.41 (dd, J = 4.5, 1.7 Hz, 1H), 7.72(dd, J = 6.5, 1.5 Hz, 1H), 7.64 – 7.58 (m, 1H), 7.33 – 7.21 (m, 6H), 5.08 (d, J = 1.0 Hz, 2H).

[0144] (4) Synthesis of compound Z47E The synthesis of compound Z47E was based on compound Z1F, except that compound Z1E was replaced by compound Z47-D.

[0145] (5) Synthesis of compound Z47F The synthesis of compound Z47F was based on compound Z1G, except that compound Z1F was replaced by compound Z47E.

[0146] (6) Synthesis of compound Z47 The synthesis of compound Z47 refers to compound Z1, except that compound Z1G is replaced by compound Z47F. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) d 8.41 (dd, J = 4.5, 1.7 Hz, 1H), 7.72(dd, J = 6.5, 1.3 Hz, 1H), 7.61 (ddd, J = 7.3, 6.5, 1.7 Hz, 1H), 7.39 – 7.21(m, 6H), 5.05 (q, J= 0.9 Hz, 2H), 3.80 (dd, J = 12.4, 5.6 Hz, 1H), 3.68 (dd, J = 12.4, 5.6 Hz, 1H), 3.64 – 3.54 (m, 2H), 2.60 (tt, J = 6.9, 5.6 Hz, 1H), 1.94 – 1.62 (m, 4H).

[0147] Embodiment 48 This example provides a method for synthesizing compound Z48, which is specifically described below. The reaction conditions are: (a) NaNO 2 , HCl, AcONa, pyridine, 0℃; (b) AcONa, AcOH, 110℃; (c) K 2 CO 3 , acetonitrile; (d) HCl, AcOH, 110 °C; (e) oxalyl chloride, DMF, DCM, N 2 ; (f) piperidine, Et 3 N, DCM, 0°C.

[0148] (1) Synthesis of compound Z48B The synthesis of compound Z48B refers to compound Z1C, except that compound Z1B is replaced by compound Z48A. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) d 9.23 (s, 1H), 7.92 (d, J = 7.6 Hz,1H), 7.85 – 7.80 (m, 2H), 7.74 (dt, J = 7.4, 1.9 Hz, 1H), 7.50 – 7.44 (m,2H), 7.37 (dd, J = 7.7, 2.2 Hz, 1H), 4.21 (q, J = 6.3 Hz, 2H), 1.27 (t, J =6.2 Hz, 3H).

[0149] (2) Synthesis of compound Z48C The synthesis of compound Z48C was based on compound Z1D, except that compound Z1C was replaced by compound Z48-B.

[0150] (3) Synthesis of compound Z48D The synthesis of compound Z48D refers to compound Z1E, except that compound Z1D is replaced by compound Z48C. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) d 8.12 (t, J = 2.0 Hz, 1H), 7.99 (d, J = 7.2 Hz, 1H), 7.93 – 7.80 (m, 2H), 7.72 (dd, J = 7.2, 2.3 Hz, 1H), 7.55 –7.41 (m, 2H), 7.36 – 7.23 (m, 5H), 5.08 (d, J = 1.1 Hz, 2H).

[0151] (4) Synthesis of compound Z48E The synthesis of compound Z48E was based on compound Z1F, except that compound Z1E was replaced by compound Z48D.

[0152] (5) Synthesis of compound Z48F The synthesis of compound Z48F was based on compound Z1G, except that compound Z1F was replaced by compound Z48E.

[0153] (6) Synthesis of compound Z48 The synthesis of compound Z48 refers to compound Z1, except that compound Z1G is replaced by compound Z48F. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) d 8.12 (t, J = 2.1 Hz, 1H), 7.99 (d, J =7.2 Hz, 1H), 7.92 – 7.80 (m, 2H), 7.72 (dd, J = 7.2, 2.3 Hz, 1H), 7.51 – 7.43(m, 2H), 7.34 – 7.23 (m, 5H), 5.20 – 4.97 (m, 2H), 3.80 (dd, J = 12.4, 5.6Hz, 1H), 3.68 (dd, J= 12.4, 5.6 Hz, 1H), 3.64 – 3.56 (m, 2H), 2.65 – 2.51 (m, 1H), 1.95 – 1.65 (m, 4H).

[0154] Embodiment 49 This embodiment provides a method for synthesizing compound Z49, which is specifically as follows. Wherein, reaction conditions (a) K 2 CO 3 , acetonitrile, 2-bromomethylpyridine; (b) HCl, glacial acetic acid, 110°C; (c) oxalyl chloride, DCM, DMF, N 2 , rt; (d) piperidine, Et 3 N, DCM, 0℃ (1) Synthesis of compound Z49-A: 500 mg (2.06 mmol) of compound Z1-D and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, 30 mL of acetonitrile was added and stirred in an ice bath, and 2-bromomethylpyridine was slowly added dropwise. After the reaction was completed, extraction was performed, the mixture was washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE:EA = 10:1) to obtain 538 mg of a white solid with a yield of 75.25%.

[0155] (2) Synthesis of compound Z49-B: 538 mg (1.55 mmol) of compound Z49-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, and 5 mL of concentrated hydrochloric acid was added, and refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid, with a yield of 70.48%.

[0156] (3) Synthesis of compound Z49-C: Place 200 mg (547.42 μmol) of compound Z49-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0157] (4) Synthesis of compound Z49: The synthesis method of compound Z49 is similar to that of Z1, except that Z1G is replaced by Z49-C. NMR data of the product: 1 H NMR (500 MHz, CDCl 3) δ 8.49 (dd, J = 4.1, 1.7Hz, 1H), 7.74 (td, J = 7.6, 1.7 Hz, 1H), 7.59 (dd, J = 7.9, 2.2 Hz, 1H), 7.52(ddd, J = 7.5, 4.2, 1.5 Hz, 1H), 7.41 (d, J = 2.1 Hz, 1H), 7.34 (dd, J = 7.8,1.4 Hz, 1H), 7.17 (dq, J = 8.0, 1.1 Hz, 1H), 5.01 – 4.77 (m, 2H), 3.80 (dd, J= 12.4, 5.6 Hz, 1H), 3.68 (dd, J = 12.4, 5.6 Hz, 1H), 3.65 – 3.53 (m, 2H), 3.26 (tt, J = 6.9, 5.6 Hz, 1H), 2.32 – 2.21 (m, 6H), 1.94 – 1.66 (m, 4H).

[0158] Embodiment 50 This example provides a method for synthesizing compound Z50, which is specifically described below. The reaction conditions are: (a) NaNO 2 , HCl, AcONa, pyridine, 0℃; (b) AcONa, AcOH, 110℃; (c) K 2 CO 3 , acetonitrile; (d) HCl, AcOH, 110 °C; (e) oxalyl chloride, DMF, DCM, N 2 ; (f) piperidine, Et 3 N, DCM, 0°C.

[0159] (1) Synthesis of compound Z50B: The synthesis of compound Z50B was carried out with reference to compound Z1C, except that compound Z1A was replaced by compound Z50A.

[0160] (2) Synthesis of compound Z50C: The synthesis of compound Z50C was carried out with reference to compound Z1D, except that compound Z1C was replaced by compound Z50B.

[0161] (3) Synthesis of compound Z50D: The synthesis of compound Z50D was carried out with reference to compound Z1E, except that compound Z1D was replaced by compound Z50C.

[0162] (4) Synthesis of compound Z50E: The synthesis of compound Z50E was carried out with reference to compound Z1F, except that compound Z1E was replaced by compound Z50D.

[0163] (5) Synthesis of compound Z50F: The synthesis of compound Z50F was carried out with reference to compound Z1G, except that compound Z1F was replaced by compound Z50E.

[0164] (6) Synthesis of compound Z50: The synthesis of compound Z50 was based on compound Z1, except that compound Z1G was replaced by compound Z50F. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) d 7.76 – 7.65 (m,4H), 7.63 – 7.56 (m, 2H), 7.48 – 7.41 (m, 2H), 7.41 – 7.34 (m, 1H), 7.34 –7.23 (m, 5H), 5.14 – 5.03 (m, 2H), 3.80 (dd, J = 12.4, 5.6 Hz, 1H), 3.68 (dd, J = 12.4, 5.6 Hz, 1H), 3.65 – 3.53 (m, 2H), 2.60 (tt, J = 6.9, 5.6 Hz, 1H), 1.93 – 1.79 (m, 2H), 1.83 – 1.66 (m, 2H).

[0165] Embodiment 51 This example provides a method for synthesizing compound Z51, which is specifically described below. The reaction conditions are: (a) NaNO 2 , HCl, AcONa, pyridine, 0℃; (b) AcONa, AcOH, 110℃; (c) K 2 CO 3 , acetonitrile; (d) HCl, AcOH, 110 °C; (e) oxalyl chloride, DMF, DCM, N 2 ; (f) Et 3 N, DCM, 0°C.

[0166] (1) Synthesis of compound Z51B: The synthesis of compound Z51B was carried out with reference to compound Z1C, except that compound Z1A was replaced by compound Z51A.

[0167] (2) Synthesis of compound Z51C: The synthesis of compound Z51C was carried out with reference to compound Z1D, except that compound Z1C was replaced by compound Z51B.

[0168] (3) Synthesis of compound Z51D: The synthesis of compound Z51D was based on compound Z1E, except that compound Z1D was replaced by compound Z51C.

[0169] (4) Synthesis of compound Z51E: The synthesis of compound Z51E was carried out with reference to compound Z1F, except that compound Z1E was replaced by compound Z51D.

[0170] (5) Synthesis of compound Z51F: The synthesis of compound Z51F was carried out with reference to compound Z1G, except that compound Z1F was replaced by compound Z51E.

[0171] (6) Synthesis of Compound Z51: The synthesis of Compound Z51 was based on the same method as Compound Z1, except that Compound Z1G was replaced by Compound Z51F. 1 H NMR (500 MHz, CDCl 3 ) d 7.73 – 7.63 (m, 4H), 7.32 – 7.24 (m, 5H), 5.13 – 5.05 (m, 2H), 3.80 (dd, J = 12.4, 5.6 Hz, 1H), 3.68 (dd, J =12.4, 5.6 Hz, 1H), 3.65 – 3.54 (m, 2H), 3.18 (s, 3H), 2.60 (tt, J = 6.9, 5.6Hz, 1H), 1.98 – 1.63 (m, 4H).

[0172] Embodiment 52 This example provides a method for synthesizing compound Z52, which is specifically described below. The reaction conditions are: (a) NaNO 2 , HCl, AcONa, pyridine, 0℃; (b) AcONa, AcOH, 110℃; (c) K 2 CO 3 , acetonitrile; (d) HCl, AcOH, 110 °C; (e) oxalyl chloride, DMF, DCM, N 2 ; (f) piperidine, Et 3 N, DCM, 0°C.

[0173] (1) Synthesis of compound Z52B: The synthesis of compound Z52B was carried out with reference to compound Z1C, except that compound Z1A was replaced by compound Z52A.

[0174] (2) Synthesis of compound Z52C: The synthesis of compound Z52C was carried out with reference to compound Z1D, except that compound Z1C was replaced by compound Z52B.

[0175] (3) Synthesis of compound Z52D: The synthesis of compound Z52D was based on the same method as compound Z1E, except that compound Z1D was replaced by compound Z52C.

[0176] (4) Synthesis of compound Z52E: The synthesis of compound Z52E was carried out with reference to compound Z1F, except that compound Z1E was replaced by compound Z52D.

[0177] (5) Synthesis of compound Z52F: The synthesis of compound Z52F was based on the same method as compound Z1G, except that compound Z1F was replaced by compound Z52E.

[0178] (6) Synthesis of compound Z52: The synthesis of compound Z52 was based on compound Z1, except that compound Z1G was replaced by compound Z52F. The NMR data of the product were: 1 H NMR (500 MHz, CDCl 3 ) d 7.70 – 7.62 (m,2H), 7.34 – 7.23 (m, 5H), 7.17 – 7.10 (m, 2H), 5.14 – 5.03 (m, 2H), 3.80 (dd,J = 12.4, 5.6 Hz, 1H), 3.68 (dd, J = 12.4, 5.6 Hz, 1H), 3.65 – 3.53 (m, 2H), 2.60 (tt, J = 6.9, 5.6 Hz, 1H), 1.93 – 1.80 (m, 2H), 1.83 – 1.73 (m, 1H), 1.76 – 1.66 (m, 1H).

[0179] Embodiment 53 This example provides a method for synthesizing compound Z53, which is specifically described below. The reaction conditions are: (a) NaNO 2 , HCl, AcONa, pyridine, 0℃; (b) AcONa, AcOH, 110℃; (c) K 2 CO 3 , acetonitrile; (d) HCl, AcOH, 110 °C; (e) oxalyl chloride, DMF, DCM, N 2 ; (f) piperidine, Et 3 N, DCM, 0°C.

[0180] (1) Synthesis of compound Z53B: The synthesis of compound Z53B was based on compound Z1C, except that compound Z1A was replaced by compound Z53A.

[0181] (2) Synthesis of compound Z53C: The synthesis of compound Z53C was carried out with reference to compound Z1D, except that compound Z1C was replaced by compound Z53B.

[0182] (3) Synthesis of compound Z53D: The synthesis of compound Z53D was based on compound Z1E, except that compound Z1D was replaced by compound Z53C.

[0183] (4) Synthesis of compound Z53E: The synthesis of compound Z53E was carried out with reference to compound Z1F, except that compound Z1E was replaced by compound Z53D.

[0184] (5) Synthesis of compound Z53F: The synthesis of compound Z53F was based on the same method as compound Z1G, except that compound Z1F was replaced by compound Z53E.

[0185] (6) Synthesis of compound Z53: The synthesis of compound Z53 was based on the same method as compound Z1, except that compound Z1G was replaced by compound Z53F. 1 H NMR (500 MHz, CDCl 3 ) δ 9.30 (s, 1H), 7.69 – 7.62 (m,2H), 7.57 – 7.51 (m, 2H), 7.34 – 7.23 (m, 5H), 5.09 (dt, J = 2.9, 0.9 Hz,2H), 3.80 (dd, J = 12.4, 5.6 Hz, 1H), 3.68 (dd, J = 12.4, 5.6 Hz, 1H), 3.65 –3.53 (m, 2H), 2.60 (tt, J = 6.9, 5.6 Hz, 1H), 2.16 (s, 2H), 1.93 – 1.80 (m, 2H), 1.83 – 1.66 (m, 2H).

[0186] Embodiment 54 This example provides a method for synthesizing compound Z54, which is specifically described below. The reaction conditions are: (a) NaNO 2 , HCl, AcONa, pyridine, 0℃; (b) AcONa, AcOH, 110℃; (c) K 2 CO3 , acetonitrile; (d) HCl, AcOH, 110 °C; (e) oxalyl chloride, DMF, DCM, N 2 ; (f) piperidine, Et 3 N, DCM, 0°C.

[0187] (1) Synthesis of compound Z54B: The synthesis of compound Z54B was carried out with reference to compound Z1C, except that compound Z1A was replaced by compound Z54A.

[0188] (2) Synthesis of compound Z54C: The synthesis of compound Z54C was carried out with reference to compound Z1D, except that compound Z1C was replaced by compound Z54B.

[0189] (3) Synthesis of compound Z54D: The synthesis of compound Z54D was based on compound Z1E, except that compound Z1D was replaced by compound Z54C.

[0190] (4) Synthesis of compound Z54E: The synthesis of compound Z54E was carried out with reference to compound Z1F, except that compound Z1E was replaced by compound Z54D.

[0191] (5) Synthesis of compound Z54F: The synthesis of compound Z54F was based on the same method as compound Z1G, except that compound Z1F was replaced by compound Z54E.

[0192] (6) Synthesis of compound Z54: The synthesis of compound Z54 was based on compound Z1, except that compound Z1G was replaced by compound Z54F. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) d 7.69 – 7.63 (m,2H), 7.34 – 7.24 (m, 5H), 7.27 – 7.19 (m, 2H), 5.14 – 5.03 (m, 2H), 3.80 (dd, J = 12.4, 5.6 Hz, 1H), 3.68 (dd, J = 12.4, 5.6 Hz, 1H), 3.65 – 3.53 (m, 2H), 2.60 (tt, J = 6.9, 5.6 Hz, 1H), 2.28 (s, 2H), 1.93 – 1.81 (m, 2H), 1.84 –1.73 (m, 1H), 1.76 – 1.66 (m, 1H).

[0193] Embodiment 55 This embodiment provides a method for synthesizing compound Z55, which is specifically as follows. Wherein, reaction conditions (a) K 2 CO 3 , acetonitrile, β-bromomethylnaphthalene; (b) HCl, glacial acetic acid, 110 °C; (c) oxalyl chloride, DCM, DMF, N 2 , rt; (d) piperidine, Et 3 N, DCM, 0°C.

[0194] (1) Synthesis of compound Z55-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath. β-bromomethylnaphthalene. After the reaction was completed, extraction was performed, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10:1) to obtain 538 mg of white solid with a yield of 75.25%.

[0195] (2) Synthesis of compound Z55-B: 538 mg (1.55 mmol) of compound Z55-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, and 5 mL of concentrated hydrochloric acid was added, and refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid, with a yield of 70.48%.

[0196] (3) Synthesis of compound Z55-C: Place 200 mg (547.42 μmol) of compound Z55-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0197] (4) Synthesis of compound Z55: The synthesis method of compound Z55 is similar to that of Z1, except that Z1G is replaced by Z55-C. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) d8.13 – 8.07 (m, 1H),7.86 – 7.78 (m, 2H), 7.77 – 7.71 (m, 1H), 7.59 (dd, J = 7.9, 2.2 Hz, 1H),7.55 – 7.43 (m, 2H), 7.41 (d, J = 2.1 Hz, 1H), 7.25 (dd, J = 8.5, 2.2 Hz, 1H), 7.17 (dq, J = 8.0, 1.1 Hz, 1H), 5.12 (s, 2H), 3.80 (dd, J = 12.4, 5.6Hz, 1H), 3.68 (dd, J = 12.4, 5.6 Hz, 1H), 3.65 – 3.53 (m, 2H), 2.64 – 2.56 (m, 1H), 2.28 (d, J = 1.1 Hz, 3H), 2.23 (s, 2H), 1.93 – 1.66 (m, 4H).

[0198] Embodiment 56 This example provides a method for synthesizing compound Z56, which is specifically described below. Wherein, reaction conditions (a) K 2 CO 3 , acetonitrile, 1-bromomethyl-3-methylsulfonylbenzene; (b) HCl, glacial acetic acid, 110 °C; (c) oxalyl chloride, DCM, DMF, N 2 , rt; (d) piperidine, Et 3 N, DCM, 0°C.

[0199] (1) Synthesis of compound Z56-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath. 1-bromomethyl-3-methylsulfonylbenzene. After the reaction was completed, extraction was performed, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10:1) to obtain 538 mg of white solid with a yield of 75.25%.

[0200] (2) Synthesis of compound Z56-B: 538 mg (1.55 mmol) of compound Z56-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, and 5 mL of concentrated hydrochloric acid was added, and refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid, with a yield of 70.48%.

[0201] (3) Synthesis of compound Z56-C: Place 200 mg (547.42 μmol) of compound Z56-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0202] (4) Synthesis of compound Z56: The synthesis method of compound Z56 is similar to that of Z1, except that Z1G is replaced by Z56-C. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) d 7.80 – 7.72 (m, 2H), 7.59 (dd, J = 7.9, 2.2 Hz, 1H), 7.46 – 7.37 (m, 3H), 7.17 (dq, J = 8.0, 1.1Hz, 1H), 5.06 (d, J = 0.9 Hz, 2H), 3.80 (dd, J = 12.4, 5.6 Hz, 1H), 3.68 (dd,J = 12.4, 5.6 Hz, 1H), 3.65 – 3.53 (m, 2H), 3.18 (s, 2H), 2.60 (tt, J = 6.9,5.6 Hz, 1H), 2.28 (d, J = 1.1 Hz, 3H), 1.93 – 1.80 (m, 2H), 1.83 – 1.73 (m,1H), 1.76 – 1.66 (m, 1H).

[0203] Embodiment 57 This embodiment provides a method for synthesizing compound Z57, which is specifically described below. Wherein, reaction conditions (a) K 2 CO 3 , acetonitrile, ethyl 3-(bromomethyl)benzoate; (b) HCl, glacial acetic acid, 110 °C; (c) oxalyl chloride, DCM, DMF, N 2 , rt; (d) piperidine, Et 3 N, DCM, 0°C.

[0204] (1) Synthesis of compound Z57-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath. 3-(bromomethyl)benzoic acid ethyl ester. After the reaction was completed, extraction was performed, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10:1) to obtain 538 mg of white solid with a yield of 75.25%.

[0205] (2) Synthesis of compound Z57-B: 538 mg (1.55 mmol) of compound Z57-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, and 5 mL of concentrated hydrochloric acid was added, and refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid, with a yield of 70.48%.

[0206] (3) Synthesis of compound Z57-C: Place 200 mg (547.42 μmol) of compound Z57-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0207] (4) Synthesis of compound Z57: The synthesis method of compound Z57 is similar to that of Z17, except that Z17-C is replaced by Z57-C. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) d 7.87 (ddd, J = 7.9, 2.4, 1.5Hz, 1H), 7.83 (tt, J = 2.2, 1.0 Hz, 1H), 7.59 (dd, J = 7.9, 2.2 Hz, 1H), 7.44– 7.37 (m, 2H), 7.39 – 7.33 (m, 1H), 7.20 – 7.14 (m, 1H), 5.15 – 5.04 (m,2H), 4.35 (q, J = 6.4 Hz, 2H), 3.80 (dd, J = 12.4, 5.6 Hz, 1H), 3.68 (dd, J=12.4, 5.6 Hz, 1H), 3.65 – 3.53 (m, 2H), 2.65 – 2.56 (m, 1H), 2.28 (d, J = 1.1Hz, 3H), 1.93 – 1.66 (m, 4H), 1.38 (t, J = 6.4 Hz, 3H).

[0208] Embodiment 58 This embodiment provides a method for synthesizing compound Z58, which is specifically as follows. Wherein, reaction conditions (a) K 2 CO 3 , acetonitrile, ethyl 3-(bromomethyl)benzoate; (b) HCl, glacial acetic acid, 110 °C; (c) oxalyl chloride, DCM, DMF, N 2 , rt; (d) piperidine, Et 3 N, DCM, 0°C.

[0209] (1) Synthesis of compound Z58-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath. 3-(bromomethyl)benzoic acid ethyl ester. After the reaction was completed, extraction was performed, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10: 1) to obtain 538 mg of white solid with a yield of 75.25%.

[0210] (2) Synthesis of compound Z58-B: 538 mg (1.55 mmol) of compound Z58-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, and 5 mL of concentrated hydrochloric acid was added, and refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid, with a yield of 70.48%.

[0211] (3) Synthesis of compound Z58-C: Place 200 mg (547.42 μmol) of compound Z58-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0212] (4) Synthesis of compound Z58: The synthesis method of compound Z58 is similar to that of Z1, except that Z1G is replaced by Z58-C. NMR data of the product: 1H NMR (500 MHz, CDCl 3 ) δ 9.10 (s, 1H), 7.59 (dd,J = 7.9, 2.2 Hz, 1H), 7.56 – 7.50 (m, 2H), 7.41 (d, J = 2.2 Hz, 1H), 7.29 –7.22 (m, 1H), 7.17 (dq, J = 8.0, 1.1 Hz, 1H), 7.14 – 7.07 (m, 1H), 5.12 –5.01 (m, 2H), 3.80 (dd, J = 12.4, 5.6 Hz, 1H), 3.68 (dd, J = 12.4, 5.6 Hz,1H), 3.65 – 3.53 (m, 2H), 2.60 (tt, J = 6.9, 5.6 Hz, 1H), 2.28 (d, J = 1.1Hz, 3H), 2.23 (s, 2H), 2.16 (s, 2H), 1.93 – 1.81 (m, 2H), 1.84 – 1.73 (m,1H), 1.76 – 1.66 (m, 1H).

[0213] Embodiment 59 This example provides a method for synthesizing compound Z59, which is specifically described below. Wherein, reaction conditions (1) K 2 CO 3 , acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N 2 , rt; (4) piperidine, Et 3 N, DCM, 0°C.

[0214] (1) Synthesis of compound Z59-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath, and 2-fluorobenzyl bromide was added. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE:EA = 10:1) to obtain 538 mg of a white solid with a yield of 75.25%.

[0215] (2) Synthesis of compound Z59-B: 538 mg (1.55 mmol) of compound Z59-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, and 5 mL of concentrated hydrochloric acid was added, and refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid, with a yield of 70.48%.

[0216] (3) Synthesis of compound Z59-C: Place 200 mg (547.42 μmol) of compound Z59-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0217] (4) Synthesis of compound Z59: The synthesis method of compound Z59 refers to the synthesis method of Z1, except that Z1G is replaced by Z59-C. NMR data of the product: 1 H NMR (300 MHz, CDCl 3 ) δ 7.47 (t, J = 7.6 Hz,1H), 7.32 (d, J = 5.7 Hz, 2H), 7.28 – 7.24 (m, 2H), 7.21 – 7.02 (m, 2H), 5.33(s, 2H), 3.75 (t, J = 4.7 Hz, 2H), 3.42 (t, J = 5.0 Hz, 2H), 2.34 (s, 6H), 1.77 - 1.63 (m, 6H).

[0218] Embodiment 60 This example provides a method for synthesizing compound Z60, which is specifically described below. Wherein, reaction conditions (1) K 2 CO 3 , acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N 2 , rt; (4) piperidine, Et 3 N, DCM, 0°C.

[0219] (1) Synthesis of compound Z60-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath, and 3-methylbenzyl bromide was added. After the reaction was completed, extraction was performed, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10:1) to obtain 538 mg of white solid with a yield of 75.25%.

[0220] (2) Synthesis of compound Z60-B: 538 mg (1.55 mmol) of compound Z60-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, 5 mL of concentrated hydrochloric acid was added, and refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid with a yield of 70.48%.

[0221] (3) Synthesis of compound Z60-C: Place 200 mg (547.42 μmol) of compound Z60-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0222] (4) Synthesis of compound Z60: The synthesis method of compound Z60 is similar to that of Z1, except that Z1G is replaced by Z60-C and piperidine is replaced by 1,4-dioxa-8-azaspiro[4.5]decane. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 7.59 (dd, J = 7.9, 2.2 Hz, 1H), 7.41 (d, J = 2.2 Hz, 1H),7.28 (ddq, J = 7.9, 2.1, 1.0 Hz, 1H), 7.20 – 7.14 (m, 2H), 7.12 (qd, J = 1.7,1.1 Hz, 1H), 7.08 (ddt, J = 7.5, 1.4, 0.8 Hz, 1H), 5.04 (t, J = 1.0 Hz, 2H),3.91 (s, 3H), 3.75 (ddd, J= 12.2, 7.4, 4.8 Hz, 2H), 3.64 (ddd, J = 12.2,7.3, 4.6 Hz, 2H), 2.32 (d, J = 0.7 Hz, 3H), 2.28 (d, J = 1.1 Hz, 3H), 1.90(dd, J = 7.3, 4.8 Hz, 2H), 1.85 (dd, J = 7.5, 4.8 Hz, 2H).

[0223] Embodiment 61 This example provides a method for synthesizing compound Z61, which is specifically described below. Wherein, reaction conditions (1) K 2 CO 3 , acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N 2 , rt; (4) piperidine, Et 3 N, DCM, 0°C.

[0224] (1) Synthesis of compound Z61-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath, and 3-hydroxybenzyl bromide was added. After the reaction was completed, extraction was performed, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10:1) to obtain 538 mg of white solid with a yield of 75.25%.

[0225] (2) Synthesis of compound Z61-B: 538 mg (1.55 mmol) of compound Z61-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, 5 mL of concentrated hydrochloric acid was added, and the mixture was refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid with a yield of 70.48%.

[0226] (3) Synthesis of compound Z61-C: Place 200 mg (547.42 μmol) of compound Z61-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0227] (4) Synthesis of compound Z61: The synthesis method of compound Z61 is similar to that of Z1, except that Z1G is replaced by Z61-C. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 7.59 (dd, J = 7.9, 2.2Hz, 1H), 7.41 (d, J = 2.1 Hz, 1H), 7.20 – 7.14 (m, 1H), 7.18 – 7.11 (m, 1H),7.07 (s, 1H), 6.96 (ddq, J = 7.9, 2.1, 1.0 Hz, 1H), 6.80 (tt, J = 2.0, 1.0Hz, 1H), 6.70 (ddd, J = 8.4, 1.8, 1.1 Hz, 1H), 5.03 (t, J = 0.9 Hz, 2H), 3.62– 3.54 (m, 2H), 3.53 – 3.45 (m, 2H), 2.28 (d, J = 1.1 Hz, 3H), 2.23 (s, 2H), 1.78 – 1.67 (m, 6H).

[0228] Embodiment 62 This example provides a method for synthesizing compound Z62, which is specifically described below. Wherein, reaction conditions (1) K 2 CO 3 , acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N 2 , rt; (4) piperidine, Et 3 N, DCM, 0°C.

[0229] (1) Synthesis of compound Z62-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath. 1-bromomethyl-3-(2-methoxyethoxy)benzene. After the reaction was completed, extraction was performed, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10:1) to obtain 538 mg of white solid with a yield of 75.25%.

[0230] (2) Synthesis of compound Z62-B: 538 mg (1.55 mmol) of compound Z62-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, and 5 mL of concentrated hydrochloric acid was added, and refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid, with a yield of 70.48%.

[0231] (3) Synthesis of compound Z62-C: Place 200 mg (547.42 μmol) of compound Z62-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0232] (4) Synthesis of compound Z62: The synthesis method of compound Z62 is similar to that of Z1, except that Z1G is replaced by Z62-C. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 7.59 (dd, J = 7.9, 2.2Hz, 1H), 7.41 (d, J = 2.1 Hz, 1H), 7.21 (q, J = 8.2 Hz, 1H), 7.20 – 7.14 (m,1H), 7.01 (ddq, J = 8.0, 2.1, 0.9 Hz, 1H), 6.91 – 6.85 (m, 2H), 5.04 (t, J =1.0 Hz, 2H), 4.05 (t, J = 4.7 Hz, 2H), 3.75 (dt, J = 6.2, 4.7 Hz, 2H), 3.62 –3.56 (m, 1H), 3.57 (tt, J = 2.1, 1.1 Hz, 1H), 3.53 – 3.45 (m, 2H), 3.06 (t, J= 6.2 Hz, 1H), 2.28 (d, J = 1.1 Hz, 3H), 1.78 – 1.68 (m, 6H).

[0233] Embodiment 63 This example provides a method for synthesizing compound Z63, which is specifically described below. Wherein, reaction conditions (1) K 2 CO 3 , acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N 2, rt; (4) piperidine, Et 3 N, DCM, 0°C.

[0234] (1) Synthesis of compound Z63-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath, and benzyl bromide was added. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10:1) to obtain 538 mg of a white solid with a yield of 75.25%.

[0235] (2) Synthesis of compound Z63-B: 538 mg (1.55 mmol) of compound Z63-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, 5 mL of concentrated hydrochloric acid was added, and the mixture was refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid with a yield of 70.48%.

[0236] (3) Synthesis of compound Z63-C: Place 200 mg (547.42 μmol) of compound Z63-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0237] (4) Synthesis of compound Z63: The synthesis method of compound Z63 is similar to that of Z1, except that Z1G is replaced by Z63-C and piperidine is replaced by azapine. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ7.59 (dd, J = 7.9, 2.2 Hz, 1H), 7.41 (d, J = 2.1 Hz, 1H), 7.34 – 7.23 (m,5H), 7.17 (dq, J = 8.0, 1.1 Hz, 1H), 5.08 (d, J = 0.9 Hz, 2H), 3.57 (t, J =6.7 Hz, 2H), 3.49 – 3.43 (m, 2H), 2.28 (d, J= 1.1 Hz, 3H), 1.72 – 1.62 (m, 4H), 1.60 – 1.49 (m, 4H).

[0238] Embodiment 64 This example provides a method for synthesizing compound Z64, which is specifically described below. Wherein, reaction conditions (1) K 2 CO 3 , acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N 2 , rt; (4) piperidine, Et 3 N, DCM, 0°C.

[0239] (1) Synthesis of compound Z64-A: 500 mg (2.06 mmol) of compound Z1-D and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath, and 3-bromomethylpyridine was added. After the reaction was completed, extraction was performed, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10:1) to obtain 538 mg of white solid with a yield of 75.25%.

[0240] (2) Synthesis of compound Z64-B: 538 mg (1.55 mmol) of compound Z64-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, and 5 mL of concentrated hydrochloric acid was added, and refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid, with a yield of 70.48%.

[0241] (3) Synthesis of compound Z64-C: Place 200 mg (547.42 μmol) of compound Z64-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0242] (4) Synthesis of compound Z64: The synthesis method of compound Z64 is similar to that of Z1, except that Z1G is replaced by Z64-C. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 8.60 (dd, J= 2.3, 1.6Hz, 1H), 8.49 – 8.43 (m, 1H), 7.73 (dt, J = 7.9, 2.2 Hz, 1H), 7.59 (dd, J =7.9, 2.2 Hz, 1H), 7.41 (d, J = 2.1 Hz, 1H), 7.28 (dd, J = 8.0, 4.2 Hz, 1H),7.17 (dq, J = 7.9, 1.0 Hz, 1H), 5.08 (s, 2H), 3.62 – 3.54 (m, 2H), 3.53 –3.45 (m, 2H), 2.28 (d, J = 1.1 Hz, 3H), 2.23 (s, 2H), 1.78 – 1.68 (m, 6H).

[0243] Embodiment 65 This example provides a method for synthesizing compound Z65, which is specifically described below. Wherein, reaction conditions (1) K 2 CO 3 , acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N 2 , rt; (4) piperidine, Et 3 N, DCM, 0°C.

[0244] (1) Synthesis of compound Z65-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath, and 3-ethylbenzyl bromide was added. After the reaction was completed, extraction was performed, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10:1) to obtain 538 mg of white solid with a yield of 75.25%.

[0245] (2) Synthesis of compound Z65-B: 538 mg (1.55 mmol) of compound Z65-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, and 5 mL of concentrated hydrochloric acid was added, and refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid, with a yield of 70.48%.

[0246] (3) Synthesis of compound Z65-C: Place 200 mg (547.42 μmol) of compound Z65-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0247] (4) Synthesis of compound Z65: The synthesis method of compound Z65 is similar to that of Z1, except that Z1G is replaced by Z65-C and piperidine is replaced by octahydro-2H-pyrido[3,4-d][1,3]oxazin-2-one. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 7.59 (dd, J = 7.9, 2.2 Hz, 1H), 7.41 (d, J = 2.1 Hz,1H), 7.33 (ddq, J = 8.2, 2.1, 1.0 Hz, 1H), 7.23 – 7.07 (m, 3H), 5.85 (d, J =7.1 Hz, 1H), 5.12 – 5.01 (m, 2H), 4.20 (ddt, J = 7.3, 5.7, 2.9 Hz, 1H), 4.19– 4.08 (m, 2H), 3.90 (dd, J = 12.5, 2.9 Hz, 1H), 3.78 (dd, J = 12.5, 2.9 Hz,1H), 3.70 – 3.58 (m, 2H), 2.68 – 2.60 (m, 2H), 2.30 – 2.21 (m, 7H), 1.79(dddd, J = 11.8, 8.4, 6.6, 5.1 Hz, 1H), 1.73 – 1.62 (m, 1H), 1.23 (t, J = 7.2 Hz, 3H).

[0248] Embodiment 66 This example provides a method for synthesizing compound Z66, which is specifically described below. Wherein, reaction conditions (1) K 2 CO 3 , acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N 2, rt; (4) piperidine, Et 3 N, DCM, 0°C.

[0249] (1) Synthesis of compound Z66-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath, and benzyl bromide was added. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10:1) to obtain 538 mg of a white solid with a yield of 75.25%.

[0250] (2) Synthesis of compound Z66-B: 538 mg (1.55 mmol) of compound Z66-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, 5 mL of concentrated hydrochloric acid was added, and the mixture was refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid with a yield of 70.48%.

[0251] (3) Synthesis of compound Z66-C: Place 200 mg (547.42 μmol) of compound Z66-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0252] (4) Synthesis of compound Z66: The synthesis method of compound Z66 is similar to that of Z1, except that Z1G is replaced by Z66-C and piperidine is replaced by 1-methyl-1,4-diazepane. NMR data of the product: 1 H NMR (500MHz, CDCl 3 ) δ 7.59 (dd, J = 7.9, 2.2 Hz, 1H), 7.41 (d, J = 2.1 Hz, 1H), 7.34– 7.23 (m, 5H), 7.17 (dq, J = 8.0, 1.1 Hz, 1H), 5.09 (t, J = 0.9 Hz, 2H),3.61 (dd, J = 7.0, 6.2 Hz, 1H), 3.57 – 3.49 (m, 2H), 3.46 (dd, J= 7.1, 6.4Hz, 1H), 2.69 (dd, J = 7.0, 6.2 Hz, 1H), 2.66 – 2.60 (m, 1H), 2.56 (ddd, J =8.4, 7.2, 6.5 Hz, 2H), 2.32 – 2.26 (m, 5H), 1.87 – 1.74 (m, 2H).

[0253] Embodiment 67 This example provides a method for synthesizing compound Z67, which is specifically described below. Wherein, reaction conditions (1) K 2 CO 3 , acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N 2 , rt; (4) piperidine, Et 3 N, DCM, 0°C.

[0254] (1) Synthesis of compound Z67-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath, and 3-ethylbenzyl bromide was added. After the reaction was completed, extraction was performed, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10:1) to obtain 538 mg of white solid with a yield of 75.25%.

[0255] (2) Synthesis of compound Z67-B: 538 mg (1.55 mmol) of compound Z67-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, and 5 mL of concentrated hydrochloric acid was added, and refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid, with a yield of 70.48%.

[0256] (3) Synthesis of compound Z67-C: Place 200 mg (547.42 μmol) of compound Z67-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0257] (4) Synthesis of compound Z67: The synthesis method of compound Z67 is similar to that of Z1, except that Z1G is replaced by Z67-C and piperidine is replaced by hexahydrooxazolo[4,5-c]pyridin-2(3H)-one. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 7.59 (dd, J = 7.9, 2.2 Hz, 1H), 7.41 (d, J = 2.1 Hz, 1H),7.33 (ddq, J = 8.2, 2.1, 1.0 Hz, 1H), 7.23 – 7.07 (m, 3H), 7.04 (s, 1H), 5.12– 5.01 (m, 2H), 4.18 (d, J = 1.8 Hz, 2H), 3.85 (d, J = 12.3 Hz, 1H), 3.75 (d, J = 12.4 Hz, 1H), 3.58 – 3.50 (m, 2H), 2.68 – 2.60 (m, 2H), 2.28 (d, J = 1.1Hz, 3H), 2.23 (s, 2H), 1.92 – 1.83 (m, 1H), 1.83 – 1.75 (m, 1H), 1.79 – 1.68(m, 2H), 1.23 (t, J = 7.2 Hz, 3H).

[0258] Embodiment 68 This example provides a method for synthesizing compound Z68, which is specifically described below. Wherein, reaction conditions (1) K 2 CO 3 , acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N 2 , rt; (4) piperidine, Et 3 N, DCM, 0°C.

[0259] (1) Synthesis of compound Z68-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath, and 3-methylbenzyl bromide was added. After the reaction was completed, extraction was performed, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10:1) to obtain 538 mg of white solid with a yield of 75.25%.

[0260] (2) Synthesis of compound Z68-B: 538 mg (1.55 mmol) of compound Z68-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, and 5 mL of concentrated hydrochloric acid was added, and refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid, with a yield of 70.48%.

[0261] (3) Synthesis of compound Z68-C: Place 200 mg (547.42 μmol) of compound Z68-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0262] (4) Synthesis of compound Z68: The synthesis method of compound Z68 is similar to that of Z1, except that Z1G is replaced by Z68-C and piperidine is replaced by 4-(1H-pyrazol-4-yl)piperidine. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 7.59 (dd, J = 7.9, 2.2 Hz, 1H), 7.43 – 7.36 (m, 2H), 7.34 (d, J =1.6 Hz, 1H), 7.28 (ddq, J = 7.9, 2.1, 1.0 Hz, 1H), 7.20 – 7.05 (m, 4H), 5.04(t, J = 1.0 Hz, 2H), 3.60 – 3.51 (m, 4H), 3.17 (p, J = 5.9 Hz, 1H), 2.32 (d, J = 0.7 Hz, 3H), 2.28 (d, J= 1.1 Hz, 3H), 2.14 (dtd, J = 12.7, 7.3, 5.9 Hz, 2H), 1.91 – 1.81 (m, 2H).

[0263] Embodiment 69 This example provides a method for synthesizing compound Z69, which is specifically described below. Wherein, reaction conditions (1) K 2 CO 3 , acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N 2 , rt; (4) piperidine, Et 3 N, DCM, 0°C.

[0264] (1) Synthesis of compound Z69-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath, and benzyl bromide was added. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10:1) to obtain 538 mg of a white solid with a yield of 75.25%.

[0265] (2) Synthesis of compound Z69-B: 538 mg (1.55 mmol) of compound Z69-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, and 5 mL of concentrated hydrochloric acid was added, and refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid, with a yield of 70.48%.

[0266] (3) Synthesis of compound Z69-C: Place 200 mg (547.42 μmol) of compound Z69-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0267] (4) Synthesis of compound Z69: The synthesis method of compound Z69 is similar to that of Z1, except that Z1G is replaced by Z69-C and piperidine is replaced by 1,4-diazepane-1-carboxylic acid tert-butyl ester. The obtained product is de-Bocated using 3M HCl in ethyl acetate to obtain product Z69. NMR data of the product: 1H NMR (500 MHz, CDCl 3 ) δ 7.59(dd, J = 7.9, 2.2 Hz, 1H), 7.41 (d, J = 2.1 Hz, 1H), 7.34 – 7.23 (m, 5H), 7.17 (dq, J = 8.0, 1.1 Hz, 1H), 5.08 (d, J = 0.9 Hz, 2H), 3.62 (t, J = 6.0Hz, 1H), 3.56 – 3.42 (m, 3H), 2.83 – 2.71 (m, 4H), 2.28 (d, J = 1.1 Hz, 3H), 2.23 (s, 2H), 2.21 – 2.13 (m, 1H), 1.89 – 1.81 (m, 1H).

[0268] Embodiment 70 This example provides a method for synthesizing compound Z70, which is specifically described below. Wherein, reaction conditions (1) K 2 CO 3 , acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N 2 , rt; (4) piperidine, Et 3 N, DCM, 0°C.

[0269] (1) Synthesis of compound Z70-A: 500 mg (2.06 mmol) of compound Z1-D and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, 30 mL of acetonitrile was added and stirred in an ice bath, and 4-fluorobenzyl bromide was added. After the reaction was completed, extraction was performed, washing with saturated NaCl solution, drying over anhydrous sodium sulfate, evaporation under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10:1) to obtain 538 mg of white solid with a yield of 75.25%.

[0270] (2) Synthesis of compound Z70-B: 538 mg (1.55 mmol) of compound Z70-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, 5 mL of concentrated hydrochloric acid was added, and refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid with a yield of 70.48%.

[0271] (3) Synthesis of compound Z70-C: Place 200 mg (547.42 μmol) of compound Z70-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0272] (4) Synthesis of compound Z70: The synthesis method of compound Z70 is similar to that of Z1, except that Z1G is replaced by Z70-C. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 7.59 (dd, J = 7.9, 2.2Hz, 1H), 7.41 (d, J = 2.1 Hz, 1H), 7.28 (ddt, J = 8.2, 5.0, 1.1 Hz, 2H), 7.17(dq, J = 8.0, 1.1 Hz, 1H), 7.13 – 7.05 (m, 2H), 5.06 (t, J = 1.0 Hz, 2H),3.62 – 3.56 (m, 1H), 3.57 (dt, J = 4.5, 1.8 Hz, 1H), 3.53 – 3.45 (m, 2H), 2.28 (d, J = 1.1 Hz, 3H), 1.78 – 1.68 (m, 6H).

[0273] Embodiment 71 This example provides a method for synthesizing compound Z71, which is specifically described below. Wherein, reaction conditions (1) K 2 CO 3 , acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N 2 , rt; (4) piperidine, Et 3 N, DCM, 0°C.

[0274] (1) Synthesis of compound Z71-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath, and benzyl bromide was added. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10:1) to obtain 538 mg of a white solid with a yield of 75.25%.

[0275] (2) Synthesis of compound Z71-B: 538 mg (1.55 mmol) of compound Z71-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, and 5 mL of concentrated hydrochloric acid was added, and refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid, with a yield of 70.48%.

[0276] (3) Synthesis of compound Z71-C: Place 200 mg (547.42 μmol) of compound Z71-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0277] (4) Synthesis of compound Z71: The synthesis method of compound Z71 is similar to that of Z1, except that Z1G is replaced by Z71-C, piperidine is replaced by piperazine-1-carboxylic acid tert-butyl ester, and the obtained product is de-Bocated using 3M HCl in ethyl acetate to obtain product Z71. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 7.59 (dd, J =7.9, 2.2 Hz, 1H), 7.41 (d, J = 2.1 Hz, 1H), 7.34 – 7.23 (m, 5H), 7.17 (dq, J = 8.0, 1.1 Hz, 1H), 5.09 (t, J = 0.9 Hz, 2H), 3.65 (dd, J = 5.7, 2.9 Hz, 2H),3.58 (dd, J = 5.8, 3.0 Hz, 2H), 2.86 (ddt, J= 22.7, 5.7, 3.1 Hz, 4H), 2.28(d, J = 1.1 Hz, 3H), 1.91 (p, J = 3.5 Hz, 1H).

[0278] Embodiment 72 This example provides a method for synthesizing compound Z72, which is specifically described below. Wherein, reaction conditions (1) K 2 CO 3 , acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N 2 , rt; (4) piperidine, Et 3 N, DCM, 0°C.

[0279] (1) Synthesis of compound Z72-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath to obtain 4-bromomethyl-1-((trimethylsilyl)methyl)-1H-1,2,3-triazole. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE:EA = 10:1) to obtain 538 mg of a white solid with a yield of 75.25%.

[0280] (2) Synthesis of compound Z72-B: 538 mg (1.55 mmol) of compound Z72-A was dissolved in 10 mL of glacial acetic acid, heated and stirred, and the temperature was raised to 70°C, and 5 mL of concentrated hydrochloric acid was added, and refluxed at 110°C. After the reaction was completed, the glacial acetic acid was evaporated under reduced pressure, and the remaining solid was washed once with water, dissolved in ether and stirred until a white solid precipitated. The solid was collected by suction to obtain 400 mg of a white solid, with a yield of 70.48%.

[0281] (3) Synthesis of compound Z72-C: Place 200 mg (547.42 μmol) of compound Z72-B in a two-necked bottle under nitrogen protection. Pour 2 mL of redistilled DCM into the two-necked bottle, add a drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the two-necked bottle. After the reaction is completed, evaporate under reduced pressure.

[0282] (4) Synthesis of compound Z72: The synthesis method of compound Z72 is similar to that of Z1, except that Z1G is replaced by Z72-C. NMR data of the product: 1 H NMR (500 MHz, CDCl 3) δ 7.63 – 7.56 (m, 2H),7.50-7.32(m, 1H), 7.17 (dq, J = 7.9, 1.0 Hz, 1H), 5.02 (s, 2H), 3.62 – 3.54(m, 2H), 3.53 – 3.45 (m, 2H), 3.16 (s, 2H), 2.28 (s, 3H), 2.23 (s, 3H), 1.78– 1.68 (m, 6H), 0.05 (s, 9H).

[0283] Embodiment 73: This example provides a method for synthesizing compound Z73, which is specifically described below. The reaction conditions are: (1) NaNO 2 , HCl, AcONa, pyridine, 0°C; (2) AcONa, AcOH, 110°C; (3) K 2 CO 3 , acetonitrile; (4) HCl, AcOH, 110°C; (5) oxalyl chloride, DMF, DCM, N 2 ; (6) piperidine, Et 3 N, DCM, 0°C.

[0284] (1) Synthesis of compound Z73-B: The synthesis of compound Z73-B was based on compound Z1C, except that compound Z1A was replaced by compound 2,3-dihydrobenzofuran-5-amine.

[0285] (2) Synthesis of compound Z73-C: The synthesis of compound Z73-C was carried out with reference to compound Z1D, except that compound Z1C was replaced by compound Z73-B.

[0286] (3) Synthesis of compound Z73-D: The synthesis of compound Z73-D was carried out with reference to compound Z1E, except that compound Z1D was replaced by compound Z73-C, and benzyl bromide was replaced by 3-methoxybenzyl bromide.

[0287] (4) Synthesis of compound Z73-E: The synthesis of compound Z73-E was based on compound Z1F, except that compound Z1E was replaced by compound Z73-D.

[0288] (5) Synthesis of compound Z73-F: The synthesis of compound Z73-F was based on compound Z1G, except that compound Z1F was replaced by compound Z73-E.

[0289] (6) Synthesis of compound Z73: The synthesis method of compound Z73 is similar to that of Z1, except that Z1G is replaced by Z73-C. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 7.42 – 7.36 (m, 2H),7.20 (dd, J = 8.1, 7.4 Hz, 1H), 7.01 (ddq, J = 8.1, 2.2, 1.1 Hz, 1H), 6.89(tt, J = 2.3, 1.0 Hz, 1H), 6.87 – 6.83 (m, 1H), 6.81 (ddd, J = 7.3, 2.2, 1.1Hz, 1H), 5.02 (t, J = 1.0 Hz, 2H), 4.50 (ddd, J = 11.4, 5.1, 3.1 Hz, 2H), 3.81 (s, 2H), 3.75 (d, J = 12.6 Hz, 1H), 3.68 (d, J = 12.6 Hz, 1H), 3.18(ddd, J = 5.1, 3.2, 0.9 Hz, 1H), 3.11 (ddd, J = 5.2, 3.2, 0.9 Hz, 1H), 2.65(dt, J = 6.2, 3.4 Hz, 4H), 1.61 – 1.53 (m, 4H), 1.49 – 1.41 (m, 2H).

[0290] Embodiment 74 This example provides a method for synthesizing compound Z74, which is specifically described below. The reaction conditions are: (1) NaNO 2 , HCl, AcONa, pyridine, 0°C; (2) AcONa, AcOH, 110°C; (3) K 2 CO 3 , acetonitrile; (4) HCl, AcOH, 110°C; (5) oxalyl chloride, DMF, DCM, N 2 ; (6) piperidine, Et 3 N, DCM, 0°C.

[0291] (1) Synthesis of compound Z74-B: The synthesis of compound Z74-B was carried out with reference to compound Z1C, except that compound Z1A was replaced by compound 2,3-dihydrobenzo[b][1,4]dioxin-6-amine.

[0292] (2) Synthesis of compound Z74-C: The synthesis of compound Z74-C was carried out with reference to compound Z1D, except that compound Z1C was replaced by compound Z74-B.

[0293] (3) Synthesis of compound Z74-D: The synthesis of compound Z74-D was carried out by referring to compound Z1E, except that compound Z1D was replaced by compound Z74-C, and benzyl bromide was replaced by 3-methoxybenzyl bromide.

[0294] (4) Synthesis of compound Z74-E: The synthesis of compound Z74-E was carried out with reference to compound Z1F, except that compound Z1E was replaced by compound Z74-D.

[0295] (5) Synthesis of compound Z74-F: The synthesis of compound Z74-F was based on compound Z1G, except that compound Z1F was replaced by compound Z74-E.

[0296] (6) Synthesis of compound Z74: The synthesis of compound Z74 was based on compound Z1, except that compound Z1G was replaced by compound Z74-F. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 7.28 (dd, J =8.2, 2.2 Hz, 1H), 7.20 (dd, J = 8.1, 7.4 Hz, 1H), 7.04 – 6.98 (m, 2H), 6.89(dp, J = 1.9, 0.9 Hz, 1H), 6.85 (d, J = 8.2 Hz, 1H), 6.81 (ddd, J = 7.3, 1.8,1.1 Hz, 1H), 5.04 (t, J = 1.0 Hz, 2H), 4.27 (s, 4H), 3.81 (s, 2H), 3.62 –3.56 (m, 1H), 3.57 (dt, J = 4.5, 1.8 Hz, 1H), 3.53 – 3.45 (m, 2H), 1.78 –1.68 (m, 6H).

[0297] Embodiment 75 This example provides a method for synthesizing compound Z75, which is specifically described below. The reaction conditions are: (1) NaNO 2 , HCl, AcONa, pyridine, 0°C; (2) AcONa, AcOH, 110°C; (3) K 2 CO 3 , acetonitrile; (4) HCl, AcOH, 110°C; (5) oxalyl chloride, DMF, DCM, N 2 ; (6) piperidine, Et 3 N, DCM, 0°C.

[0298] (1) Synthesis of compound Z75-B: The synthesis of compound Z75-B was based on compound Z1C, except that compound Z1A was replaced by compound 2-methyl-2H-indazol-5-amine.

[0299] (2) Synthesis of compound Z75-C: The synthesis of compound Z75-C was carried out with reference to compound Z1D, except that compound Z1C was replaced by compound Z75-B.

[0300] (3) Synthesis of compound Z75-D: The synthesis of compound Z75-D was carried out by referring to compound Z1E, except that compound Z1D was replaced by compound Z75-C, and benzyl bromide was replaced by 3-methoxybenzyl bromide.

[0301] (4) Synthesis of compound Z75-E: The synthesis of compound Z75-E was based on compound Z1F, except that compound Z1E was replaced by compound Z75-D.

[0302] (5) Synthesis of compound Z75-F: The synthesis of compound Z75-F was based on compound Z1G, except that compound Z1F was replaced by compound Z75-E.

[0303] (6) Synthesis of compound Z75: The synthesis of compound Z75 was based on compound Z1, except that compound Z1G was replaced by compound Z75-F. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 8.10 (t, J = 2.0Hz, 1H), 7.94 (d, J = 1.8 Hz, 1H), 7.75 (dd, J = 6.7, 2.3 Hz, 1H), 7.62 (d, J = 6.8 Hz, 1H), 7.20 (dd, J= 8.1, 7.4 Hz, 1H), 7.01 (ddq, J = 8.1, 2.1, 1.0Hz, 1H), 6.89 (tt, J = 1.9, 1.0 Hz, 1H), 6.81 (ddd, J = 7.3, 1.8, 1.1 Hz,1H), 5.04 (t, J = 1.0 Hz, 2H), 3.93 (s, 3H), 3.81 (s, 2H), 3.62 – 3.56 (m,1H), 3.57 (tt, J = 2.1, 1.1 Hz, 1H), 3.53 – 3.45 (m, 2H), 1.78 – 1.68 (m, 6H).

[0304] Embodiment 76 This example provides a method for synthesizing compound Z76, which is specifically described below. The reaction conditions are: (1) NaNO 2 , HCl, AcONa, pyridine, 0°C; (2) AcONa, AcOH, 110°C; (3) K 2 CO 3 , acetonitrile; (4) HCl, AcOH, 110°C; (5) oxalyl chloride, DMF, DCM, N 2 ; (6) piperidine, Et 3 N, DCM, 0°C.

[0305] (1) Synthesis of compound Z76-B: The synthesis of compound Z76-B was based on compound Z1C, except that compound Z1A was replaced by compound 2,3-dihydro-1H-inden-5-amine.

[0306] (2) Synthesis of compound Z76-C: The synthesis of compound Z76-C was carried out with reference to compound Z1D, except that compound Z1C was replaced by compound Z76-B.

[0307] (3) Synthesis of compound Z76-D: The synthesis of compound Z76-D was carried out by referring to compound Z1E, except that compound Z1D was replaced by compound Z77-C, and benzyl bromide was replaced by 3-methoxybenzyl bromide.

[0308] (4) Synthesis of compound Z76-E: The synthesis of compound Z76-E was carried out with reference to compound Z1F, except that compound Z1E was replaced by compound Z76-D.

[0309] (5) Synthesis of compound Z76-F: The synthesis of compound Z76-F was based on compound Z1G, except that compound Z1F was replaced by compound Z76-E.

[0310] (6) Synthesis of compound Z76: The synthesis of compound Z76 was based on compound Z1, except that compound Z1G was replaced by compound Z76-F. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 7.41 (dd, J =1.9, 1.0 Hz, 1H), 7.32 (dd, J = 8.0, 1.9 Hz, 1H), 7.24 – 7.17 (m, 2H), 7.01(ddq, J = 8.1, 2.1, 0.9 Hz, 1H), 6.89 (tt, J = 2.0, 0.9 Hz, 1H), 6.81 (ddd, J = 7.3, 1.8, 1.1 Hz, 1H), 5.04 (t, J = 1.0 Hz, 2H), 3.81 (s, 2H), 3.62 – 3.56(m, 1H), 3.57 (dt, J = 4.5, 1.8 Hz, 1H), 3.53 – 3.45 (m, 2H), 2.91 – 2.81 (m,4H), 2.16 – 2.04 (m, 2H), 1.78 – 1.67 (m, 6H).

[0311] Embodiment 77 This example provides a method for synthesizing compound Z77, which is specifically described below. The reaction conditions are: (1) NaNO 2 , HCl, AcONa, pyridine, 0°C; (2) AcONa, AcOH, 110°C; (3) K 2 CO 3 , acetonitrile; (4) HCl, AcOH, 110°C; (5) oxalyl chloride, DMF, DCM, N 2 ; (6) piperidine, Et 3 N, DCM, 0°C.

[0312] (1) Synthesis of compound Z77-B: The synthesis of compound Z77-B was based on compound Z1C, except that compound Z1A was replaced by compound 5,6,7,8-tetrahydronaphthalene-2-amine.

[0313] (2) Synthesis of compound Z77-C: The synthesis of compound Z77-C was carried out with reference to compound Z1D, except that compound Z1C was replaced by compound Z77-B.

[0314] (3) Synthesis of compound Z77-D: The synthesis of compound Z77-D was carried out by referring to compound Z1E, except that compound Z1D was replaced by compound Z77-C, and benzyl bromide was replaced by 3-methoxybenzyl bromide.

[0315] (4) Synthesis of compound Z77-E: The synthesis of compound Z77-E was carried out with reference to compound Z1F, except that compound Z1E was replaced by compound Z77-D.

[0316] (5) Synthesis of compound Z77-F: The synthesis of compound Z77-F was based on compound Z1G, except that compound Z1F was replaced by compound Z77-E.

[0317] (6) Synthesis of compound Z77: The synthesis of compound Z77 was based on compound Z1, except that compound Z1G was replaced by compound Z77-F. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 7.34 – 7.29 (m,2H), 7.20 (dd, J = 8.1, 7.4 Hz, 1H), 7.13 (dt, J = 8.5, 1.1 Hz, 1H), 7.01(ddq, J = 8.1, 2.1, 0.9 Hz, 1H), 6.89 (tt, J = 1.9, 0.9 Hz, 1H), 6.81 (ddd, J = 7.3, 1.8, 1.1 Hz, 1H), 5.04 (t, J = 1.0 Hz, 2H), 3.81 (s, 2H), 3.62 – 3.56(m, 1H), 3.57 (tt, J = 2.1, 1.1 Hz, 1H), 3.53 – 3.45 (m, 2H), 2.82 – 2.70 (m,4H), 1.79 – 1.72 (m, 3H), 1.75 – 1.67 (m, 7H).

[0318] Embodiment 78 This example provides a method for synthesizing compound Z78, which is specifically described below. The reaction conditions are: (1) NaNO 2 , HCl, AcONa, pyridine, 0°C; (2) AcONa, AcOH, 110°C; (3) K 2 CO 3 , acetonitrile; (4) HCl, AcOH, 110°C; (5) oxalyl chloride, DMF, DCM, N 2 ; (6) piperidine, Et 3 N, DCM, 0°C.

[0319] (1) Synthesis of compound Z78-B: The synthesis of compound Z78-B was carried out with reference to compound Z1C, except that compound Z1A was replaced by compound 2-propyl-1,2,3,4-tetrahydroisoquinolin-7-amine.

[0320] (2) Synthesis of compound Z78-C: The synthesis of compound Z78-C was carried out with reference to compound Z1D, except that compound Z1C was replaced by compound Z78-B.

[0321] (3) Synthesis of compound Z78-D: The synthesis of compound Z78-D was carried out by referring to compound Z1E, except that compound Z1D was replaced by compound Z78-C, and benzyl bromide was replaced by 3-methoxybenzyl bromide.

[0322] (4) Synthesis of compound Z78-E: The synthesis of compound Z78-E was carried out with reference to compound Z1F, except that compound Z1E was replaced by compound Z78-D.

[0323] (5) Synthesis of compound Z78-F: The synthesis of compound Z78-F was based on compound Z1G, except that compound Z1F was replaced by compound Z78-E.

[0324] (6) Synthesis of compound Z78: The synthesis of compound Z78 was based on compound Z1, except that compound Z1G was replaced by compound Z78-F. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 7.58 (dd, J =7.9, 2.2 Hz, 1H), 7.47 (dt, J = 2.2, 1.1 Hz, 1H), 7.25 – 7.17 (m, 2H), 7.01(ddq, J = 8.1, 2.1, 0.9 Hz, 1H), 6.89 (tt, J= 1.9, 0.9 Hz, 1H), 6.81 (ddd, J = 7.3, 1.8, 1.1 Hz, 1H), 5.04 (t, J = 1.0 Hz, 2H), 3.81 (s, 2H), 3.71 (dd, J = 12.4, 1.1 Hz, 1H), 3.63 (dd, J = 12.5, 1.1 Hz, 1H), 3.62 – 3.54 (m, 2H), 3.53 – 3.45 (m, 2H), 2.94 – 2.75 (m, 5H), 2.53 (t, J = 6.2 Hz, 2H), 1.78 –1.68 (m, 6H), 1.51 (qt, J = 7.9, 6.2 Hz, 2H), 0.89 (t, J = 7.9 Hz, 3H).

[0325] Embodiment 79 This example provides a method for synthesizing compound Z79, which is specifically described below. The reaction conditions are: (1) NaNO 2 , HCl, AcONa, pyridine, 0°C; (2) AcONa, AcOH, 110°C; (3) K 2 CO 3 , acetonitrile; (4) HCl, AcOH, 110°C; (5) oxalyl chloride, DMF, DCM, N 2 ; (6) piperidine, Et 3 N, DCM, 0°C.

[0326] (1) Synthesis of compound Z79-B: The synthesis of compound Z79-B was carried out with reference to compound Z1C, except that compound Z1A was replaced by compound 6,7-dihydro-5H-cyclopenta[b]pyridine-3-amine.

[0327] (2) Synthesis of compound Z79-C: The synthesis of compound Z79-C was carried out with reference to compound Z1D, except that compound Z1C was replaced by compound Z79-B.

[0328] (3) Synthesis of compound Z79-D: The synthesis of compound Z79-D was carried out by referring to compound Z1E, except that compound Z1D was replaced by compound Z79-C, and benzyl bromide was replaced by 3-methoxybenzyl bromide.

[0329] (4) Synthesis of compound Z79-E: The synthesis of compound Z79-E was carried out with reference to compound Z1F, except that compound Z1E was replaced by compound Z79-D.

[0330] (5) Synthesis of compound Z79-F: The synthesis of compound Z79-F was based on compound Z1G, except that compound Z1F was replaced by compound Z79-E.

[0331] (6) Synthesis of compound Z79: The synthesis of compound Z79 was based on compound Z1, except that compound Z1G was replaced by compound Z79-F. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 8.47 (d, J = 2.0Hz, 1H), 8.18 (d, J = 2.0 Hz, 1H), 7.20 (dd, J = 8.1, 7.4 Hz, 1H), 7.01 (ddq, J = 8.1, 2.1, 1.0 Hz, 1H), 6.89 (tt, J = 1.9, 0.9 Hz, 1H), 6.81 (ddd, J =7.3, 1.8, 1.1 Hz, 1H), 5.04 (t, J = 1.0 Hz, 2H), 3.81 (s, 2H), 3.62 – 3.56(m, 1H), 3.57 (dq, J = 3.3, 2.1, 1.7 Hz, 1H), 3.53 – 3.45 (m, 2H), 2.98 (dd, J = 7.0, 5.2 Hz, 1H), 2.95 – 2.85 (m, 3H), 2.32 – 2.20 (m, 2H), 1.78 – 1.68 (m, 6H).

[0332] Embodiment 80 This example provides a method for synthesizing compound Z80, which is specifically described below. The reaction conditions are: (1) NaNO 2 , HCl, AcONa, pyridine, 0°C; (2) AcONa, AcOH, 110°C; (3) K 2 CO 3 , acetonitrile; (4) HCl, AcOH, 110°C; (5) oxalyl chloride, DMF, DCM, N 2; (6) piperidine, Et 3 N, DCM, 0°C.

[0333] (1) Synthesis of compound Z80-B: The synthesis of compound Z80-B was based on compound Z1C, except that compound Z1A was replaced by compound 5,6-dimethylpyridin-3-amine.

[0334] (2) Synthesis of compound Z80-C: The synthesis of compound Z80-C was carried out with reference to compound Z1D, except that compound Z1C was replaced by compound Z80-B.

[0335] (3) Synthesis of compound Z80-D: The synthesis of compound Z80-D was carried out by referring to compound Z1E, except that compound Z1D was replaced by compound Z80-C, and benzyl bromide was replaced by 3-methoxybenzyl bromide.

[0336] (4) Synthesis of compound Z80-E: The synthesis of compound Z80-E was carried out with reference to compound Z1F, except that compound Z1E was replaced by compound Z80-D.

[0337] (5) Synthesis of compound Z80-F: The synthesis of compound Z80-F was based on compound Z1G, except that compound Z1F was replaced by compound Z80-E.

[0338] (6) Synthesis of compound Z80: The synthesis of compound Z80 was based on compound Z1, except that compound Z1G was replaced by compound Z80-F. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 8.38 (d, J = 1.8Hz, 1H), 7.77 (d, J = 2.0 Hz, 1H), 7.20 (dd, J = 8.1, 7.4 Hz, 1H), 7.01 (ddq, J = 8.1, 2.2, 1.0 Hz, 1H), 6.89 (tt, J = 2.0, 0.9 Hz, 1H), 6.81 (ddd, J =7.3, 1.8, 1.1 Hz, 1H), 5.04 (t, J= 1.0 Hz, 2H), 3.81 (s, 2H), 3.62 – 3.54(m, 2H), 3.53 – 3.45 (m, 2H), 2.38 (s, 2H), 2.29 (s, 2H), 1.78 – 1.68 (m,5H).

[0339] Embodiment 81 This example provides a method for synthesizing compound Z81, which is specifically described below. The reaction conditions are: (1) NaNO 2 , HCl, AcONa, pyridine, 0°C; (2) AcONa, AcOH, 110°C; (3) K 2 CO 3 , acetonitrile; (4) HCl, AcOH, 110°C; (5) oxalyl chloride, DMF, DCM, N 2 ; (6) piperidine, Et 3 N, DCM, 0°C.

[0340] (1) Synthesis of compound Z81-B: The synthesis of compound Z81-B was carried out with reference to compound Z1C, except that compound Z1A was replaced by compound 2-methylisoindolin-5-amine.

[0341] (2) Synthesis of compound Z81-C: The synthesis of compound Z81-C was carried out with reference to compound Z1D, except that compound Z1C was replaced by compound Z81-B.

[0342] (3) Synthesis of compound Z81-D: The synthesis of compound Z81-D was carried out by referring to compound Z1E, except that compound Z1D was replaced by compound Z81-C, and benzyl bromide was replaced by 3-methoxybenzyl bromide.

[0343] (4) Synthesis of compound Z81-E: The synthesis of compound Z81-E was carried out with reference to compound Z1F, except that compound Z1E was replaced by compound Z81-D.

[0344] (5) Synthesis of compound Z81-F: The synthesis of compound Z81-F was based on compound Z1G, except that compound Z1F was replaced by compound Z81-E.

[0345] (6) Synthesis of compound Z81: The synthesis of compound Z81 was based on compound Z1, except that compound Z1G was replaced by compound Z81-F. NMR data of the product: 1 H NMR (500 MHz, CDCl 3 ) δ 7.57 (dd, J=8.2, 2.2 Hz, 1H), 7.52 (dt, J = 2.1, 1.0 Hz, 1H), 7.24 – 7.16 (m, 2H), 7.01(ddq, J = 8.1, 2.1, 1.0 Hz, 1H), 6.89 (tt, J = 1.9, 1.0 Hz, 1H), 6.81 (ddd, J = 7.3, 1.8, 1.1 Hz, 1H), 5.04 (t, J = 1.0 Hz, 2H), 3.93 – 3.87 (m, 4H), 3.81 (s, 2H), 3.62 – 3.56 (m, 1H), 3.57 (tt, J = 2.1, 1.1 Hz, 1H), 3.53 – 3.45 (m,2H).

[0346] Embodiment 82 This example provides a method for synthesizing compound Z82, which is specifically shown below.

[0347] Synthesis of compound Z82-A: 3,4-dimethylboric acid (500 mg, 4.46 mmol), uracil (1340 mg, 8.92 mmol), copper acetate (1640 mg, 4.46 mmol) and N,N,N',N'-tetramethylethylenediamine (1040 mg, 8.92 mmol) were dissolved in a mixed solution of 400 ml MeOH and 100 ml water and left at room temperature overnight. Most of the solvent was removed by rotary evaporation, and part of the solvent was removed, extracted with ethyl acetate, and the organic phase was purified by spin column chromatography to obtain white solid Z82-A. 1 H NMR (500 MHz, CDCl 3 ) δ 9.89 (s, 1H), 8.22 (d, J = 7.3 Hz, 1H), 7.31 (d, J = 1.7 Hz, 1H),7.17 – 6.97 (m, 2H), 5.87 (d, J = 7.3 Hz, 1H), 2.28 (s, 1H), 2.22 (s, 3H).

[0348] Synthesis of compound Z82-B: The synthesis of compound Z82-B was based on the synthesis of compound Z15-A, except that compound Z1-D was replaced by Z82-A.

[0349] Synthesis of compound Z82-C: Z82-B (650 mg) was placed in a double-necked bottle, and 1 ml of anhydrous DMF was added to dissolve under nitrogen protection. In an EP tube, 0.7 ml of dry DMF was added, and 0.5 ml of POCl was slowly added. 3 , then slowly drip it into the DMF solution of Z82-B under ice bath conditions. Heat to 90°C for two hours to end the reaction. Use 2N NaOH aqueous solution to quench the reaction. Use ethyl acetate to extract, dry the organic phase with anhydrous sodium sulfate, and remove the organic solvent by vacuum distillation. Purify by column chromatography to obtain a white solid Z82-C.

[0350] Synthesis of compound Z82-D: Dissolve Z82-C (110 mg) in a mixed solvent of 6 ml tert-butyl alcohol and 6 ml tetrahydrofuran, and drop 1 ml 2-methyl-2-butene. Dissolve sodium dihydrogen phosphate (264 mg) and sodium chlorite (76 mg) in water and slowly add to the solution of Z82-D. After 1 h of reaction at room temperature, remove the solvent by rotary evaporation, then adjust the pH to acidic with 1N HCl, extract with ethyl acetate, and dry with anhydrous sodium sulfate. Remove the solvent by rotary evaporation to obtain white solid Z82-D.

[0351] Synthesis of compound Z82: Compound Z82-D (114 mg) was dissolved in 2 ml of anhydrous dichloromethane, and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (74 mg), 1-hydroxybenzotriazole (53 mg), and piperidine (33 mg) were added in sequence under ice bath conditions. The reaction was allowed to proceed at room temperature for 5 h, and the reaction was completed. Water was added for extraction, and the organic phase was dried over anhydrous sodium sulfate. The organic solvent was removed by rotary evaporation and purified by column chromatography to obtain white solid Z82. 1 H NMR (500 MHz, CDCl 3 ) δ 8.50 (s,1H), 7.27 – 7.17 (m, 2H), 7.14 – 7.09 (m, 1H), 7.06 (dd, J = 8.1, 2.2 Hz,1H), 7.01 (ddq, J = 8.1, 2.1, 1.0 Hz, 1H), 6.89 (tt, J = 1.9, 0.9 Hz, 1H),6.81 (ddd, J = 7.3, 1.8, 1.1 Hz, 1H), 5.04 (t, J = 1.0 Hz, 2H), 3.81 (s, 3H), 3.59 – 3.53 (m, 1H), 3.53 (dd, J= 4.4, 1.8 Hz, 1H), 3.51 – 3.47 (m, 1H), 3.47 (ddd, J = 8.8, 3.4, 2.0 Hz, 1H), 2.28 (s, 3H), 2.22 (s, 3H), 1.79 – 1.68 (m, 6H).

[0352]

[0353] Embodiment 83 This example provides a method for synthesizing compound Z83. Synthesis of compound Z83: Compound Z82-C and sodium acetate borohydride are placed in a double-necked flask, 7 ml of anhydrous dichloromethane is added under nitrogen protection, and then piperidine is dripped into the double-necked flask, and the reaction is terminated at room temperature overnight. After adding saturated sodium bicarbonate aqueous solution and stirring for half an hour, dichloromethane is used for extraction, dried over anhydrous sodium sulfate, the organic solvent is removed by rotary evaporation, and purified by column chromatography to obtain white solid Z83. 1 H NMR (500 MHz, CDCl 3 )δ 8.25 (s, 1H), 7.26 – 7.24 (m, 2H), 7.20 (dd, J = 8.1, 7.4 Hz, 2H), 7.11(dq, J = 8.1, 1.0 Hz, 2H), 7.07 (dd, J = 8.1, 2.2 Hz, 2H), 7.01 (ddq, J =8.1, 2.2, 1.1 Hz, 2H), 6.89 (tt, J = 1.9, 0.9 Hz, 2H), 6.81 (ddd, J = 7.3,1.8, 1.1 Hz, 2H), 5.01 (s, 2H), 3.81 (s, 4H), 3.71 (d, J = 1.0 Hz, 3H), 2.57(dd, J = 6.2, 3.5 Hz, 2H), 2.53 (dd, J = 6.2, 3.5 Hz, 2H), 2.28 (s, 3H), 2.22(s, 3H), 1.60 – 1.52 (m, 4H), 1.48 – 1.42 (m, 2H).

[0354] Embodiment 84 The synthesis of compound Z84 was based on the synthesis of Z17, except that 3-methylbenzyl bromide was replaced by 3-methoxyphenethyl bromide in the synthesis of Z17. 1 H NMR (500 MHz, CDCl 3 ) δ 7.59 (dd, J = 7.9, 2.2Hz, 1H), 7.41 (d, J = 2.1 Hz, 1H), 7.21 – 7.14 (m, 2H), 6.92 (ddq, J = 7.7,2.2, 1.1 Hz, 1H), 6.78 (ddd, J = 7.5, 2.2, 1.1 Hz, 1H), 6.73 (tt, J = 2.2,1.0 Hz, 1H), 4.11 (t, J = 6.5 Hz, 2H), 3.80 (s, 3H), 3.62 – 3.56 (m, 2H), 3.53 – 3.45 (m, 2H), 2.92 (tt, J = 6.5, 1.1 Hz, 2H), 2.28 (s, 3H), 2.23 (s, 2H), 1.78 – 1.68 (m, 6H).

[0355] Embodiment 85 The synthesis of compound Z85 refers to the synthesis of Z17, except that 3-methylbenzyl bromide in the synthesis of Z17 was replaced by 3-methoxyphenylpropyl bromide. 1 H NMR (500 MHz, CDCl 3 ) δ 7.59 (dd, J = 7.9, 2.2Hz, 1H), 7.41 (d, J = 2.1 Hz, 1H), 7.21 – 7.14 (m, 2H), 6.86 (ddq, J = 7.7,2.1, 1.0 Hz, 1H), 6.78 (ddd, J = 7.5, 2.0, 1.2 Hz, 1H), 6.71 (tt, J = 2.0,1.0 Hz, 1H), 3.95 (dt, J = 12.6, 6.9 Hz, 1H), 3.84 (dt, J= 12.7, 6.8 Hz,1H), 3.80 (s, 2H), 3.62 – 3.56 (m, 1H), 3.57 (tt, J = 2.1, 1.1 Hz, 1H), 3.53– 3.45 (m, 2H), 2.69 (tt, J = 8.5, 1.0 Hz, 2H), 2.28 (d, J = 1.1 Hz, 3H), 2.23 (s, 2H), 1.93 (tt, J = 8.4, 6.9 Hz, 2H), 1.78 – 1.68 (m, 6H).

[0356] Embodiment 86 This example provides a method for synthesizing compound Z86, which is specifically shown below.

[0357] (1) Synthesis of compound Z86-A: Compound Z15-A (489 mg) and Pd / C (1440 mg, 5%) were placed in a double-necked flask, and 20 ml of methanol and 2 ml of concentrated hydrochloric acid were added under hydrogen. The reaction was allowed to proceed overnight at room temperature. The mixture was filtered using diatomaceous earth, and the filtrate was rotary evaporated to remove the organic solvent to obtain a white solid. The solid was dissolved in water and precipitated with NaHCO 3 The saturated aqueous solution was adjusted to an alkaline pH, extracted with dichloromethane, dried over anhydrous sodium sulfate, and the organic solvent was removed by rotary evaporation. The colorless and transparent oil Z86-A was obtained by column chromatography. 1 H NMR (500 MHz, CDCl 3 ) δ 7.59 (dd, J = 7.9, 2.2 Hz, 1H),7.41 (d, J = 2.2 Hz, 1H), 7.20 (dd, J = 8.1, 7.5 Hz, 1H), 7.17 (dq, J = 7.9,0.9 Hz, 1H), 7.01 (ddq, J = 8.1, 2.1, 0.9 Hz, 1H), 6.89 (dp, J = 1.9, 0.9 Hz,1H), 6.81 (ddd, J = 7.3, 1.8, 1.1 Hz, 1H), 5.02 (t, J = 1.0 Hz, 2H), 4.14(dt, J= 13.3, 6.6 Hz, 1H), 4.06 (dt, J = 13.2, 6.7 Hz, 1H), 3.81 (s, 3H), 2.93 (t, J = 6.7 Hz, 2H), 2.28 (d, J = 1.1 Hz, 3H), 2.23 (s, 3H).

[0358] (2) Synthesis of compound Z86: Z86-A and sodium acetate borohydride were placed in a double-necked flask, and anhydrous dichloromethane was added to dissolve under nitrogen protection, and cyclohexanone was added. The reaction was completed at room temperature overnight. After adding saturated sodium bicarbonate aqueous solution and stirring for half an hour, dichloromethane was used for extraction, and the mixture was dried over anhydrous sodium sulfate. The organic solvent was removed by rotary evaporation, and the white solid Z86 was purified by column chromatography. 1 H NMR (500 MHz, CDCl 3 ) δ 7.59 (dd, J = 7.9, 2.2 Hz, 1H), 7.41 (d, J =2.2 Hz, 1H), 7.20 (dd, J = 8.1, 7.5 Hz, 1H), 7.17 (dq, J = 7.9, 0.9 Hz, 1H),7.01 (ddq, J = 8.1, 2.1, 0.9 Hz, 1H), 6.89 (tt, J = 2.0, 0.9 Hz, 1H), 6.81(ddd, J = 7.3, 1.8, 1.1 Hz, 1H), 5.02 (s, 2H), 3.81 (s, 3H), 3.56 (dd, J =15.4, 5.9 Hz, 1H), 3.48 (dd, J = 15.3, 5.9 Hz, 1H), 2.78 (dp, J = 6.6, 4.6Hz, 1H), 2.60 (dt, J = 6.6, 5.9 Hz, 1H), 2.28 (d, J = 1.1 Hz, 3H), 2.23 (s, 3H), 1.72 – 1.31 (m, 10H).

[0359]

[0360] Embodiment 87 The synthesis method of compound Z87 refers to the synthesis of Z86, except that the cyclohexanone in the synthesis process of Z86 is replaced by tetrahydro-pyran-4-one, and the NMR 1 H NMR (500 MHz, CDCl 3 ) δ 7.59 (dd, J = 7.9,2.2 Hz, 1H), 7.41 (d, J = 2.2 Hz, 1H), 7.20 (dd, J = 8.1, 7.5 Hz, 1H), 7.17(dq, J = 7.9, 1.0 Hz, 1H), 7.01 (ddq, J = 8.1, 2.1, 0.9 Hz, 1H), 6.89 (dp, J = 2.0, 1.0 Hz, 1H), 6.81 (ddd, J = 7.3, 1.8, 1.1 Hz, 1H), 5.02 (s, 2H), 3.81(s, 2H), 3.68 – 3.62 (m, 1H), 3.65 – 3.61 (m, 1H), 3.57 (ddd, J = 12.3, 5.8,3.1 Hz, 3H), 3.48 (dd, J = 15.3, 5.9 Hz, 1H), 2.92 (dp, J = 6.4, 4.8 Hz, 1H),2.70 (q, J = 6.0 Hz, 1H), 2.28 (d, J = 1.1 Hz, 3H), 2.23 (s, 1H), 1.83 (dddd, J = 12.4, 5.9, 4.8, 3.2 Hz, 2H), 1.59 (dddd, J = 12.4, 5.7, 4.8, 3.2 Hz, 2H).

[0361] Embodiment 88 The synthesis method of compound Z88 refers to the synthesis of Z86, except that the cyclohexanone in the synthesis process of Z86 is replaced by tetrahydropyran-4-carboxaldehyde, and the NMR 1 H NMR (500 MHz, CDCl 3) δ 7.59 (dd, J = 7.9,2.2 Hz, 1H), 7.41 (d, J = 2.2 Hz, 1H), 7.24 – 7.14 (m, 2H), 7.01 (ddq, J =8.1, 2.1, 0.9 Hz, 1H), 6.89 (dp, J = 2.0, 1.0 Hz, 1H), 6.81 (ddd, J = 7.3,1.8, 1.1 Hz, 1H), 5.02 (s, 2H), 3.81 (s, 2H), 3.65 – 3.60 (m, 1H), 3.60 (d, J = 4.9 Hz, 2H), 3.58 (s, 1H), 3.57 – 3.53 (m, 1H), 3.57 – 3.50 (m, 1H), 3.26(p, J = 6.2 Hz, 1H), 2.80 (ddd, J = 12.8, 6.0, 4.4 Hz, 1H), 2.67 (ddd, J =12.8, 6.0, 4.5 Hz, 1H), 2.28 (d, J = 1.1 Hz, 3H), 2.23 (s, 1H), 1.79 – 1.68 (m, 3H), 1.57 – 1.46 (m, 2H).

[0362] Embodiment 89 The synthesis method of compound Z89 refers to compound Z82, except that Z82-D in the synthesis process of Z82 is replaced by 1-methylpiperidine-4-carboxylic acid, and piperidine is replaced by Z86-A. 1 H NMR (500 MHz, CDCl 3 ) δ7.75 (t, J = 6.3 Hz, 1H), 7.59 (dd, J = 7.9, 2.2 Hz, 1H), 7.41 (d, J = 2.2Hz, 1H), 7.23 – 7.13 (m, 2H), 7.01 (ddq, J = 8.1, 2.1, 1.0 Hz, 1H), 6.89 (tt, J= 2.0, 1.0 Hz, 1H), 6.81 (ddd, J = 7.3, 1.8, 1.1 Hz, 1H), 5.04 (t, J = 1.0Hz, 2H), 4.02 (d, J = 6.4 Hz, 2H), 3.81 (s, 2H), 2.76 (ddd, J = 12.3, 8.8,6.1 Hz, 2H), 2.52 (ddd, J = 12.5, 8.8, 6.2 Hz, 2H), 2.39 (p, J = 5.5 Hz, 1H),2.28 (d, J = 1.1 Hz, 3H), 2.27 (s, 3H), 2.23 (s, 3H), 1.89 – 1.73 (m, 4H).

[0363] Test Example 1: Determination of the inhibitory activity of compounds on human MDA-MB-231 breast cancer cells and MCF-10A normal breast epithelial cells The present invention uses human MDA-MB-231 breast cancer and MCF-10A normal breast epithelial cell lines to detect antitumor activity, and the drug concentration gradient is set to 0, 0.1μM, 0.2μM, 0.4μM, 0.8μM, 1μM, and 3×10 3 Cells / well were seeded in a 96-well plate. After 72 hours of drug treatment, the cell activity was detected by CCK-8 method, and the half inhibitory concentration was determined. That is, after treatment, 10 μM CCK-8 reagent was added to each well, incubated for 2 hours, and the absorbance was read at a wavelength of 450 nm. The results are shown in Tables 1 and 2.

[0364] As shown in Table 1, 1,2,4-triazine-3,5(2H,4H)-dione compounds have good inhibitory activity against triple-negative breast cancer MDA-MB-231 cells, while R 1 and R 2 The amide derivative Z13, which is all H, completely lost its activity, suggesting the importance of the 6-substituted amide structure of 1,2,4-triazine-3,5(2H,4H)-dione in inhibiting the activity of triple-negative breast cancer MDA-MB-231 cells.

[0365] Table 1 Inhibitory effect of compounds on breast cancer MDA-MB-231 cells at a concentration of 20 μM

[0366] Among them, *** represents a strong inhibition rate, that is, an inhibition rate of more than 80%; ** represents a medium inhibition rate, that is, an inhibition rate of 60-80%; * represents a low inhibition rate, that is, an inhibition rate of 40-60%; NA represents no activity, that is, an inhibition rate of less than 30%. The asterisk is used to make the technical effect of the present invention more intuitive and clear.

[0367] As shown in Table 2, the IC values ​​of representative compounds against triple-negative breast cancer cells MDA-MB-231 and normal breast cancer cells MCF-10A were tested. 50 Activity. The literature shows that the IC of paclitaxel for MDA-MB-231 50 =1μM (Cong HJ et al. JNat Prod. 2013), IC for MCF-10A 50 =5.64nM (Journal of Cellular Physiology (2019), 234, (4), 4277-4290). Compared with paclitaxel, the compounds protected by the present invention have higher MDA-MB-231 cell inhibitory activity, that is, stronger in vitro anti-tumor inhibitory activity, especially compound Z37, which has an activity of about 100nM, while the activity against MCF-10A cells is weak (IC 50 >10μM), that is, 1,2,4-triazine-3,5(2H,4H)-dione compounds have strong antitumor activity and low toxicity. Figure 4 As shown in Figure A, representative compounds Z19 and Z37 also showed strong cell activity against other breast cancer cells.

[0368] Table 2 Inhibitory activity of representative compounds against breast cancer MDA-MB-231 cells and normal breast cells MCF-10A cells

[0369] Test Example 2: Determination of the binding activity of compounds to eEF2K The present invention uses the SPR method (surface plasmon resonance method) to detect the binding ability of Z1-E, Z4, Z5, Z42, Z12, Z14, and Z18 to eEF2K. The SPR experiment was performed using Amersham Life Sciences 110397-04. A 1mM / L compound was prepared in DMSO and fixed on the photocrosslinker SensorCHIPTM. The eEF2K protein was diluted with PBST to concentrations of 200 nM, 400 nM, 1600 nM, and 3200 nM, respectively, and PBST was used as a running buffer. The eEF2K protein was injected at a flow rate of 0.5 μL / s for 600 s. The experiment was performed from low concentration to high concentration; the regeneration solution glycine hydrochloride (pH = 2.0) was used to regenerate at a flow rate of 2 μL / s. The detection time for the dissociation process was 360 s. The laboratory temperature was 4°C. The raw data collected on the SPR biosensor were further processed to remove any artifacts such as nonspecific binding and differences in buffer composition. Figure 4 Middle C. As shown in the figure, representative compounds Z4, Z5, Z42, Z12, Z14, and Z18 showed strong binding ability with eEF2K, that is, the compounds selectively targeted the eEF2K protein.

[0370] Test Example 3: Determination of the degradation activity of compounds on eEF2K The present invention uses westemm blotting to detect the effects of different concentrations of Z19 and Z37 on the expression of eEF2K protein in MDA-MB-231 and BT549 cells. The specific steps are as follows: After adding different concentrations of Z19 and Z37 for treatment (0, 50nM, 100nM, 200mM, 400mM, 800nM) for 48h, the cells were lysed with RIPA buffer containing a protease inhibitor cocktail and a phosphatase inhibitor. The cell lysate was centrifuged at 12000×g for 15 minutes at 4°C. The protein concentration of the supernatant was determined by the Bradford assay. A total of 20 g of protein samples were subjected to SDS-PAGE and transferred to a PVDF membrane (0.22 m, Merek Millipore). After blocking with skim milk, the membrane was incubated with the corresponding primary antibody and then coupled with the secondary antibody HRP. The protein signal was detected by an enhanced chemiluminescence kit. The results are shown in Figure 4 In B, it can be clearly seen that Z19 and Z37 inhibited the expression of eEF2K protein in a dose-dependent manner.

[0371] In addition, the effects of compounds Z1, Z4, Z15, Z16, Z17, Z18, Z19, Z23, Z24, Z28, Z45, Z53, Z59, Z63, Z73, Z74, Z75, Z76, Z77, Z78, Z79, and Z80 on the expression of eEF2K protein in MDA-MB-231 cells at a concentration of 1 uM were determined by the above method. As shown in Table 3, almost all compounds of the present invention can inhibit the expression of eEF2K protein.

[0372] Table 3 Degradation rate of eEF2K protein in breast cancer MDA-MB-231 cells by compounds at 1 μM concentration

[0373] Among them, *** represents a strong degradation rate, that is, a degradation rate of more than 70%; ** represents a medium inhibition rate, that is, an inhibition rate of 50-70%; * represents a low inhibition rate, that is, an inhibition rate of 20-50%; NA represents no activity, that is, an inhibition rate of less than 20%. The asterisk is used to make the technical effect of the present invention more intuitive and clear.

[0374] Test Example 4: Animal experiment on the anti-tumor activity of the compound.

[0375] The present invention uses paclitaxel (PTX) as a positive control to measure the effect of compound Z19 on tumor proliferation at doses of 5 mg / kg and 10 mg / kg. The specific experimental steps are as follows: MDA-MB-231 cells (1×106 / mouse) were suspended in 100 μL DMEM and then subcutaneously injected into the right side of 4-week-old female nude mice. Each group has six mice. The tumor-bearing mice were randomly divided into groups. When the tumor size reached 70-80 mm 3 Treatment was started at 1.5 ng / ml (volume = length × width 2 × π / 6). The mice were randomly divided into several groups and treated for the next 16 days. Tumor volume and mouse weight were measured every other day. Figure 5 As shown in A and B, at the same dose as PTX, compound Z19 showed an efficacy similar to that of PTX. And as the treatment time increases, compound Z19 shows an anti-tumor effect superior to that of PTX.

[0376] In addition, while determining the anti-tumor activity of the compounds, the toxic and side effects of the compound treatment on the experimental animals were also determined. Figure 5As shown in C and D, the experimental results show that compound Z19 did not show obvious toxic side effects, and the heart, liver, spleen, lung, and kidney of the mice in the Z19-treated group did not show obvious lesions. In terms of weight changes, the weight of the mice in the PTX group decreased significantly as the treatment time increased. No weight loss was found in the 5mg / kg group and the 10mg / kg group of compound Z19.

[0377] In summary, the diketone compounds (1,2,4-triazine-3,5 (2H,4H)-diketone compounds) disclosed in the present invention show strong anti-malignant tumor cell activity by targeting eEF2K protein while having little effect on normal cell activity, showing strong anti-tumor potential and high safety, and thus have great application prospects.

[0378] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.

Claims

1. A diketone compound, characterized in that The structural formula of the diketone compound is shown in Formula A: ; in, , are independently selected from substituted or unsubstituted aryl or heteroaryl; X is carbonyl or alkyl; Y is substituted or unsubstituted alkyl; Z is N or CH; R1 and R2 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclic, ester, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, both of which cannot be hydrogen at the same time; or R1 and R2 together with the nitrogen atom to which they are connected form a substituted or unsubstituted heterocyclic group; R1 and R2 may be the same or different.

2. The diketone compound according to claim 1, characterized in that The R1 and R2 are substituted by several R3; the R3 is selected from one or more of halogen, C1-C6 alkyl, haloalkyl, silane, aralkyl, heteroaryl, alkoxy, hydroxyl, hydroxyalkoxy, hydroxyalkyl, alkoxyalkoxy, alkoxyalkyl, aminealkyl, aminealkoxy, amino, alkylamino, hydroxyalkylamino, aminealkylamino, alkoxyacyl, alkoxycarbonylamino, cyano, acyloxy, acyl, sulfonyl, carbamoyl, sulfonylamino, urea, nitro, and thiourea; in the substituted or unsubstituted alkyl, the carbon number of the alkyl is 1 to 10; the substituted or unsubstituted heteroaryl In the cyclic group, the heterocycle is a 3-8 membered monocyclic ring or a 6-20 membered polycyclic ring; in the substituted alkyl group, the substituted heterocyclic group, the substituted alkenyl group, the substituted alkynyl group, and the substituted aryl group, the substituents are independently selected from one or more of halogen, alkyl, alkoxy, haloalkyl, silyl, aralkyl, heteroaryl, hydroxyl, hydroxyalkoxy, hydroxyalkyl, alkoxyalkoxy, alkoxyalkyl, aminealkyl, aminealkoxy, amino, alkylamino, hydroxyalkylamino, aminealkylamino, alkoxyacyl, alkoxycarbonylamino, sulfonylamino, urea, thiourea, cyano, nitro, acyloxy, acyl, sulfonyl, and carbamoyl.

3. The diketone compound according to claim 1, characterized in that The substituted or unsubstituted aryl or heteroaryl group is a substituted or unsubstituted benzene ring, a naphthalene ring, a biphenyl ring, or an aromatic heterocycle composed of one or more N, O, and S. In the substituted or unsubstituted aryl or heteroaryl group, the substituent groups include one or more of hydrogen, alkyl, haloalkyl, silane, aralkyl, heteroaryl, alkoxy, haloalkoxy, hydroxyl, hydroxyalkoxy, hydroxyalkyl, alkoxyalkoxy, alkoxyalkyl, aminealkoxy, amino, aminealkyl, alkylamino, hydroxyalkylamino, aminealkylamino, alkoxyacyl, alkoxycarbonylamino, sulfonylamino, urea, thiourea, halogen, cyano, acyloxy, nitro, carbamoyl, acyl, and sulfonyl.

4. The diketone compound according to claim 3, characterized in that The substituted or unsubstituted heteroaryl group is selected from one or more of a substituted or unsubstituted pyrrole ring, a pyrazole ring, a furan ring, a thiophene ring, a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, an imidazole ring, a pyridine ring, a pyrazine ring, a pyrimidine ring, a pyridazine ring, a triazole, a naphthalene ring, a benzoaromatic heterocycle, and a benzocycloalkane.

5. The diketone compound according to claim 1, characterized in that The diketone compound is the following compound: ; ; ; ; 6. A method for preparing a diketone compound as claimed in any one of claims 1 to 5, characterized in that: The invention comprises the following preparation methods: Method 1: (1) subjecting the compound represented by formula A1 to a compound represented by formula A2 through a diazotization coupling reaction to obtain a compound represented by formula A3; (2) The compound represented by formula A3 is subjected to ring closure under acidic conditions to obtain the compound represented by formula A4, and the compound represented by formula A4 undergoes substitution reaction with a halogenated hydrocarbon under alkaline conditions to obtain the compound represented by formula A5; (3) The cyano group of the compound represented by formula A5 is hydrolyzed under acidic conditions to obtain a compound represented by formula A6 containing a carboxylic acid; (4) The compound represented by formula A6 is prepared into an acyl chloride compound represented by formula A7, and reacted with an amine compound to obtain a compound represented by formula A, i.e., the diketone compound; Or method 2: (1) reacting the compound represented by formula B1 with the compound represented by formula B2 to obtain the compound represented by formula B3; (2) the compound represented by formula B3 reacts under alkaline conditions to obtain the compound represented by formula B4, and the compound represented by formula B4 reacts to obtain the compound represented by formula B5; (3) the compound represented by formula B5 is reacted to obtain the compound represented by formula B6 containing carboxylic acid; or the compound represented by formula B5 is reacted with an amine compound to obtain the diketone compound; (4) The compound represented by formula B6 reacts with an amine compound to prepare the diketone compound; Or method three: (1) reacting the cyano group of the compound represented by formula A5 to obtain the compound represented by formula C2 containing an amine group; (2) preparing the diketone compound from the compound represented by formula C2; The structural formula of the above compound is as follows: ; ; The structural formula of the amine compound is shown below: 。 7. The preparation method according to claim 6, characterized in that: In method one, the molar ratio of the compound represented by formula A1 to the compound represented by formula A2 is 1:1-1:2, the acidic condition is a pH value of 1-4; the alkaline condition is a pH value of 8-10, and the compound represented by formula A6 is subjected to an acyl chloride reaction under the action of a catalyst to prepare an acyl chloride compound represented by formula A7; in method two, the reaction of the compound represented by formula B1 and the compound represented by formula B2 is carried out under a copper salt catalyst and an alkali catalyst, the compound represented by formula B3 is reacted under an inorganic alkali compound condition to obtain a compound represented by formula B4, and the compound represented by formula B4 is reacted under a phosphorus catalyst to obtain a compound represented by formula B5; in method three, the cyano group of the compound represented by formula A5 is reacted under hydrogen and a noble metal catalyst to obtain an amine-containing compound represented by formula C2, the compound represented by formula C2 is reacted with an amine compound to prepare the diketone compound, or the compound represented by formula C2 is reacted with a carboxylic acid compound to prepare the diketone compound.

8. An anti-tumor drug, characterized in that: The active ingredient of the anti-tumor drug comprises the diketone compound and its isomer or pharmaceutically acceptable salt or hydrate according to any one of claims 1 to 5.

9. Use of the diketone compound and its isomers or pharmaceutically acceptable salts or hydrates according to any one of claims 1 to 5 in the preparation of malignant tumor drugs or in the preparation of eukaryotic elongation factor kinase 2 inhibitors.

10. The use according to claim 9, characterized in that: The malignant tumor is selected from triple-negative breast cancer, esophageal cancer, lung cancer, colon cancer, breast cancer, rectal cancer, liver cancer, gastric cancer, thyroid cancer, prostate cancer, cervical cancer, uterine cancer, pancreatic cancer, ovarian cancer, bladder cancer, brain tumor, blood tumor, lymphoma, etc.

Citation Information

Patent Citations

  • Novel triazinedione derivatives as GABAB receptor modulators

    CN101679354A

  • New targeting antitumor drug and preparation method and application thereof

    CN103992236A

  • Substituted uracils as chymase inhibitors

    CN105873919A

  • Oxaazaquinazoline-7(8H)-ketone compound, preparation method therfor and pharmaceutical application thereof

    CN113767106A

  • Application of 2-aminoindole compound in antitumor drugs

    CN115054599A